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ABSTRACT

The first chapter of this dissertation serves as an overview of the background and
significance of this study, the associations between hereditary breast cancer susceptibility
gene alterations (GA) and aggressive tumor phenotypes in women with breast cancer.
The body of work in all chapters focuses on the topics of breast cancer genomics,
inflammatory breast cancer, the application of Protection Motivation Theory to guide
prevention strategies for women with breast cancer diagnosis and positive genetic
alteration, and the associations between hereditary breast cancer susceptibility GAs and
aggressive tumor phenotype.
The second chapter is a review of literature to discuss breast cancer genomics,
specifically two genes, Ataxia Telangiectasia Mutated (ATM) and the Partner and
Localizer of BRCA2 (PALB2). The results of the review highlight the importance of
identifying two new breast cancer susceptibility genes, other than the well known BRCA1
and BRCA2, and the requirement of including these genes in standard breast cancer
genetic testing.
The third chapter is a review of literature to describe inflammatory breast cancer
(IBC), pathogenicity of the disease and genomic investigation of IBC. IBC is an
aggressive type of breast cancer with poor prognosis responsible for 2.5% of all new
breast cancers. The majority of IBC patients are diagnosed with triple negative breast
cancer (TNBC), which is the aggressive phenotype.
The fourth chapter provides an overview of literature that describes the Protection
Motivation Theory (PMT) and how it has been applied in a variety of research settings.
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A pilot study is suggested including PMT and its application for breast cancer prevention
strategies uptake by patients who have a diagnosis of breast cancer. The pilot study
would use a focus group of women with breast cancer to determine if the theory can
guide prevention strategies for women with a mutation that causes the high risk to
develop multiple types of primary cancers over their lifetime.
The fifth chapter describes the dissertation work; a quantitative study that
analyzes associations between aggressive breast cancer phenotypes in a population of
women at high risk for hereditary breast cancer and specific GAs.
The final chapter, is a synthesis of all manuscripts related to the breast cancer in
the high risk population of women to develop this dreaded disease; breast cancer genomic
investigation of ATM and PALB2 genes, the aggressive IBC, PMT application for breast
cancer prevention strategies uptake and association of GAs and aggressive breast cancer
phenotype. The populations in all the articles were women diagnosed with breast cancer
and were at high risk of hereditary breast cancer syndromes.
As a result of these manuscripts, it is expected to make suggestions for genetic
testing guidelines to include multi-panel genetic testing for all eligible individuals as well
as inclusion of tumor biomarkers and ethnicity in eligibility criteria. It is also
recommended to apply PMT to encourage adherence to prevention strategies in order to
reduce the risk of additional cancer primary.
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CHAPTER ONE
INTRODUCTION

The American Cancer Society predicted 231,840 new cases of invasive breast cancer
and 60,290 cases of breast carcinoma in situ to be diagnosed in 2015 (American Cancer
society, 2015). Despite an increasing body of knowledge and clear standardized
recommendations, there remain a number of women who do not follow breast cancer
screening (34%), prevention and early detection strategies (less than 0.2% of women in
United States use Tamoxifen and approximately 3% of Australian women follow the
prevention guidelines) (American Cancer Society, 2015; Cancer Genome Atlas Network,
2012; Evans, Lalloo, Shenton, Boggis, & Howell, 2001; Ralph et al., 2014).
Almost 10 % (approximately 20,000) of breast cancer cases are due to germline
mutations (Tung, et al., 2015). Studies targeting tumor biology of breast cancer and
epidemiology of the disease have been utilized to guide prevention, early detection and
risk reduction (Cancer Genome Atlas Network, 2012; Ralph et al., 2014; Youlden et al.,
2012). It is especially important that hereditary breast cancer gene mutation carriers with
risk for early onset breast cancer follow strategies to detect the malignancy early (Fositra
et al., 2012; Gonzalez- Angulo et al., 2011; Lee et al., 2011).
Technologic advances in human genomics, in combination with faster and less costly
gene sequencing results, have enhanced the research for the advancement of targeted
therapy of molecular biomarkers (Grada, & Weinbrecht, 2013; Hawthorn, Luce, Stei, &
Rothschild, 2010; Staren, et al., 2014). Incorporation of genetic information using new
technologies and utilizing the vast research available have given us the resources to
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identify breast cancer earlier when it may be more treatable and with less invasive
methods and to predict patient outcome.
Commonly found factors associated with a mutation related to a hereditary breast
cancer syndrome include: 1) family history of breast cancer with close blood relatives
(three generations) who are diagnosed at younger age (under the age of 50) or at least two
blood relatives diagnosed with breast cancer at any age; 2) one close family member with
ovarian cancer; or, 3) two blood relatives with pancreatic cancer (NCCN, 2015).
Environmental factors, also known as exogenous factors (such as carcinogen exposures)
as well as endogenous factors could impact breast cancer onset (See Table 1.1) (Kushi, et
al., 2012; Li, 2009). Endogenous factors affecting breast cancer were the variables that
were included in this study.
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Table 1.1
Endogenous and exogenous factors in cancer
Endogenous Cause of Cancer

Exogenous Cause of Cancer

Hereditary
Age
Hormones
Ethnic background

Environmental factors
Tobacco use
Radiation therapy
UV exposure
Diet and lifestyle
Carcinogen exposure
Note. (Catsburg, Miller, & Rohan, 2014; Kushi et al., 2012; Li, 2009).
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Breast cancer incidence and biomarkers are influenced by ethnicity and race.
African American women in the United States tend to be diagnosed with a more
aggressive type of breast cancer as compared to Caucasian women (Boone, et al., 2014;
Iqbal, et al., 2015). African American women are diagnosed at a younger age while
Caucasian women have a higher incidence after the age of 40, however, the screening and
prevention guidelines is not specifically focused on this ethnic group (Gail et al., 2007;
Iqbal et al., 2015; NCCN, 2015). Researchers propose that the variation could be due to
their lifestyle, diet and family history (Gail et al., 2007; Iqbal et al., 2015).
Individuals, who are carriers for a mutated gene associated with one of the
hereditary syndromes, consistent with the autosomal dominant inheritance pattern
commonly seen in cancer, have a higher risk of breast cancer at a younger age of onset
than sporadic cancer. The breast cancers associated with damaged germline DNA are
often bilateral plus an increased incidence of other types of cancer (Bernstein et al., 2010;
Tischkowitz et al., 2012).
There is a potential knowledge gap in applying the genetic information and in
incorporating prevention strategies into practice specifically in diverse population. This
knowledge gap was utilized to develop a plan of dissertation study. The primary purpose
of this body of work was to look at aggressive features associated with breast cancer and
to identify potential strategies to combat the troubling phenomena. This lead to the
following aims:
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1. Identify factors associated with the aggressive nature of inflammatory breast
cancer;
2. Review the nature of two new breast cancer susceptibility genes;
3. Describe a theory that has the potential to motivate women at high risk to develop
an aggressive cancer to pursue prevention and screening strategies;
4. Determine if breast cancer susceptibility genetic alterations (GA) are associated
with an aggressive tumor phenotype in women with a new diagnosis of breast
cancer; and,
5. Determine if the aggressive breast cancer tumor phenotype is associated with a
specific gene variant(s).
It is well described that cancer is a genetic disorder caused by both acquired and
inherited mutations (Knudson, 1996; Previati, et al., 2013; Rich, Woodson, Litton, &
Arun, 2015; Wooster, et al., 1994). Acquired changes, such as the changes in DNA that
occur over a lifetime that are caused by environmental factors including, radiation
exposure, age and viruses. The acquired changes include an increase in function caused
by gene fusions, insertions, duplications and translocations and alteration of tumor
suppressor activity through rearrangements and deletions (Previati, et al., 2013;
Sebestyen, Zawisza, & Eyras, 2015). Inherited mutations, also known as germline
mutations are passed on from parents to their children and appear in all cells (Knudson,
1996; Wooster, et al., 1994). Breast cancer genetic studies have shown a correlation
between BRCA1 and BRCA2 mutations as well as particular tumor types like triple
negative breast cancer (TNBC)— an aggressive type of breast cancer (Atchley, et al.,
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2008; Lee, et al., 2011; Young, et al., 2009). TNBC has also been reported in mutations
of PALB2 (Pern, et al., 2012).
Germline mutations in BRCA1/2 genes are associated with other tissue types of
cancer including ovarian cancer (BRCA1 with an average lifetime risk of 39 % and
BRCA2 with an average risk of 45%), pancreatic cancer (BRCA1 with relative risk (RR)
of 2.3, BRCA2 with RR of 3.5) and prostate cancer (BRCA1 with RR of 1.8, BRCA2 RR
of 4.6) (Castro, et al., 2013; Maier, et al., 2014; Mersch, et al., 2015; Moran, et al., 2012;
Petrucelli & Feldman, 2010).
In addition to high penetrance mutations in BRCA1/2 (the only two genes that are
tested together), PTEN and TP53 (TP53 is seen in one percent of hereditary breast
cancers) (Sidransky, et al., 1992), there are other genes that have moderate to high
penetrance and are included in multi-gene panel testing for breast cancer syndromes
including: CDH1, STK11, EPCAM, MLH1, MSH2, MSH6, PMS2 and STK11 (high risk
genes); CHEK2, PALB2 and ATM (moderate risk genes); and also include LH1, MSH2,
MSH6, PMS2, BARD1, BRIP1, RAD51C and RAD51D (NCCN, 2015; Schroeder, et al.,
2015; Tung, et al., 2015).
Three manuscripts of this dissertation were developed to address the necessity of
achieving a better understanding of aggressive breast cancer phenotype and its underlying
genetic causes and to state the potential gap in applying the genetic information and
incorporating prevention strategies into practice particularly in different ethnic
backgrounds. The organization of this dissertation begins with Manuscript I (Chapter 2),
“Breast Cancer Genomics.” This section investigates two breast cancer susceptibility
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genes, ATM and PALB2 and presents updates on guidelines for genetic testing through a
comprehensive review of literature. These guidelines offer options to treat women who
could previously have had less than potential cure for their cancer. The results of the
review highlight the importance of identifying two new breast cancer susceptibility
genes, other than the well known BRCA1 and BRCA2, to be included in genetic testing
for hereditary breast cancer syndromes and to offer personalized treatment and disease
management based on the results.
Beyond the well-known peau d’orange sign at presentation, the second
Manuscript (Chapter 3), “Inflammatory Breast Cancer,” discusses IBC and how GAs
may affect the disease. IBC is a more aggressive type of breast cancer and commonly
found to be triple negative breast cancer. This manuscript carefully describes
inflammatory immune response and inflammation mechanism involved in tumorigenesis.
Treatment and management of the disease is described and based on a comprehensive
review of literature.
The third Manuscript (Chapter 4), entitled “Use Of Protection Motivation Theory
To Guide Prevention Strategies In Women With Breast Cancer Diagnosis And a Positive
Genetic Alteration,” investigates literature related to PMT with application to breast
cancer prevention, early detection and cancer management. This theory has previously
been used in different research studies applying constructs and concepts of Roger’s PMT
to educate and urge women with breast cancer to follow the strategies to prevent second
primaries (Bui et al., 2013; Karmakar, 2013; Lee et al., 2007; Moy, Park, Feibelmann,
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Chiang, & Weissman, 2006; Ralph et al., 2014; Vogel, 2015). This manuscript proposes a
pilot study to improve motivation of this population of women to follow the guidelines.
Chapter 5 describes a quantitative study, entitled “Associations Between
Hereditary Breast Cancer Susceptibility GAs And Aggressive Tumor Phenotype in
Women Diagnosed With Breast Cancer.” The purpose of this study was to determine if
genetic mutation and/or variants of unknown significance (VUS) predict aggressive
breast cancer phenotype. This study enrolled 101 women with a breast cancer diagnosis
and an increased risk for germline mutation(s) associated with a hereditary breast cancer
syndrome. The results suggest a new use of multi-gene panel genetic testing for women
with breast cancer, specifically from different ethnic backgrounds.
Chapter 6 synthesizes information presented from the body of work to present the
conclusions developed by the author as guided by the chair and committee. Limitations of
the study are acknowledged, implications for future research are presented and future
plans for the researcher are addressed.
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CHAPTER TWO
BREAST CANCER GENOMICS
(Submitted on 10/05/15, Clinical Journal of Oncology Nursing)
Abstract
The American Cancer Society (ACS) predicts 231,840 new cases of invasive
breast cancer and 60,290 cases of breast carcinoma in situ to be diagnosed in 2015
(American Cancer Society, 2015). Excluding non-melanoma skin cancer, breast cancer is
the most common type of cancer in U.S. women; responsible for approximately 14% of
new cancer diagnoses (National Cancer Institute, 2014). There are currently 28 genes
included in the National Comprehensive Cancer Network (NCCN) guidelines for testing
of genetic mutations associated with hereditary breast cancer, including ataxia
telangiectasia mutated (ATM) and the partner and localizer of BRCA2 (PALB2) genes
(NCCN, 2015; Schroeder et al., 2015; Tung et al., 2015).
The purpose of this article is to provide an update on breast cancer genomics
targeting two lesser-known pathogenic gene mutations recently added to the NCCN
guidelines; ATM and PALB2 (NCCN, 2015). A comprehensive review and synthesis of
current literature was completed to describe recent information on ATM and PALB2 and
recommendations for the detection and treatment of breast cancer caused by these two
gene mutations. Recent advances in genetics-related breast cancer research, testing and
clinical implications are stressed. Healthcare providers play a critical role in breast cancer
care and are actively engaged with patients and their families. This manuscript offers an
update to information in order to understand the latest advances in breast cancer
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genomics and to translate the new genomic knowledge into clinical practice in order to
provide the ultimate in patient care.
Methods
A comprehensive literature search of PubMed, Google Scholar, CINAL, ProQuest
Nursing and Allied Health, Cochrane Database and Web of Science was conducted using
the search terms “breast cancer,” “high risk breast cancer,” “breast cancer genes,”
“ATM,” “BRCA1/2,” “PALB2,” “breast cancer genetic testing,” and “breast cancer
genomics.” The search generated 146 articles from 2009-2015. Original research articles
with a focus on the genetics of ATM and PALB2 genes, their variations as well as
molecular pathways with comparison to other hereditary breast cancer genes were
selected. Exclusion criteria included articles that were not in English, papers not related
to breast cancer, research articles with a lack of evidence and animal studies. Careful
evaluation of all the articles identified 26 quantitative studies relevant to the purpose of
the project.
Introduction
Numerous studies have been conducted on the topic of breast cancer over the past
few years. Advances in DNA sequencing have helped scientists make progress in cancer
screening, prevention and treatment (Chin, Hahn, Getz, & Meyerson, 2011; Grada, &
Weinbrecht, 2013; Hawthorn, Luce, Stei, & Rothschild, 2010; Staren, et al., 2014).
Innovations in technology targeting human genomics (See Table 2.1) have led to superior
biomedical research results via expression profiling, DNA microarray, array comparative
genomic hybridization, next-generation sequencing (NGS) and massive parallel
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sequencing providing valuable genetic information with detailed, faster and more reliable
results. Developing a better understanding of breast cancer and reducing testing costs will
help providers to implement more personalized decisions for every patient (Chin, Hahn,
Getz, & Meyerson, 2011; Grada, & Weinbrecht, 2013; Hawthorn, Luce, Stei, &
Rothschild, 2010; Staren, et al., 2014). There are limitations to each of these techniques.
Overall massive data requires highly trained professionals to analyze the data and
supercomputers to store the outcome (Grada, & Weinbrecht, 2013; Previati, et al., 2013).
The National Comprehensive Cancer Network (NCCN) guidelines recently
published a new list of breast cancer susceptibility genes, including ataxia telangiectasia
mutated (ATM) and partner and localizer of BRCA2 (PALB2) genes, to their guidelines
(NCCN, 2015). The guidelines addressed the updates based on current breast cancer
research to provide eligibility criteria for genetic testing and new strategies for providers
and education for patients. According to the newest version of the guidelines (version
2.2015 published in March), patients must meet one or more of breast cancer risk
assessment criteria to be eligible for genetic testing for hereditary breast and ovarian
cancer (HBOC) syndrome (NCCN, 2015). The additions of new genes lead us to the
importance of a comprehensive review of literature specifically on the lesser-known
genes to better detect and manage breast cancer and not to focus only on BRCA1/2 genes.
The main objective of this review is to address characteristics of the two new novel breast
cancer genes with a discussion of relevance to treatment, patient education and care.

Ataxia Telangiectasia Mutated (ATM)
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Ataxia telangiectasia mutated protein (ATM protein) is encoded by the ATM gene,
is part of the phosphoinositide-3 kinase (PI3)/phosphoinositide-4 protein kinase (PI4)
family and plays an important role in the repair of DNA double strand breaks. ATM
protein kinase is an enzyme that phosphorylates proteins involved in DNA double strand
damage repair in order to maintain DNA stability (Goldgar, et al., 2011). By promoting a
delay in the G1 phase of the cell cycle, there is time to repair the DNA before progressing
through the rest of the phases. This delay for repair prevents double strand breaks from
being established in the new cells (Khoronenkova & Dianov, 2015; Goldgar, et al., 2011).
The repair of double strand breaks is crucial for DNA stability. If the damage is not
repaired and replication continues, uncontrolled proliferation of the damaged DNA could
result in the development of cancer (Khoronenkova & Dianov, 2015).
Ionizing radiation is a carcinogen that causes a double strand break of the DNA.
Therefore, patients with already mutated genes are at higher risk of cancer when exposed
to ionizing radiation causing additional DNA breakage (Goldgar, et al., 2011; Bernstein,
et al., 2010). There are some other carcinogens causing DNA breakage including H.
Pylori, which is a bacterial carcinogen (Toller et al., 2011), chemical carcinogens such as
arsenic (Litwin, Bocer, Dziadkowiec, & Wysocki, 2013) and monocrotophos that is an
extremely toxic pesticide (Zhao, Wang, Zhang, Tian, Wang, & Ru, 2015).
The ATM gene is involved in a series of molecular pathways associated with
genes such as TP53, checkpoint kinase 2 (CHEK2) and BRCA1, all resulting in
phosphorylation of the proteins that eventually end with apoptosis, DNA repair and cell
cycle checkpoints arrest; important in DNA stability (Bernstein, et al., 2010). People with
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deleterious ATM missense variants, such as BRCA1/2 and CHEK2 mutations, are also at
higher risk of developing second breast cancers due to lack of repair mechanisms if they
are treated with radiation (Bernstein, et al., 2010). The ATM protein is part of the
signaling cascade called ATM-CHEK2-p53; CHEK2 protein and tumor protein p53
(TP53). The ATM protein activates p53 and CHEK2 proteins in response to toxic stress
to the cell (Knappskog, et al., 2012). ATM genetic mutations have also been associated
with an increased incidence of breast cancer (Knappskog, et al., 2012).
Knappskog, et al. (2012) assessed the role of ATM mutation in the development of
chemotherapy resistance for patients with breast cancer. They conducted gene expression
profiling using tumor biopsy samples from participants (N = 71) before starting a
neoadjuvant chemotherapy regimen. The researchers found that the ATM-CHEK2-p53
cascade associated with DNA damage repair was responsible for chemotherapy resistance
in participants receiving anthracycline/mitomycin-containing regimens.
Typically the p53 and the CHEK2-ATM pathways are responsible for repairing
DNA damage due to chemotherapy; mutations or reduction of expression of any genes in
the cascade may be the cause for the patient to be resistant to chemotherapy. An
alternative regimen, such as vinca alkaloids, can be suggested instead of the
anthracycline/mitomycin regimen that causes resistance and allows the tumor to continue
to grow (Knappskog, et al., 2012). Since ATM is normally involved in the DNA double
strand damage repair pathway, women with a pathogenic mutation will have DNA
instability, due to DNA damage and cell proliferation. These individuals are at higher risk
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of contralateral breast cancer diagnosis after their initial radiation therapy (Bernstein, et
al., 2010).
One study identified a rare variant of the ATM gene (c.7271T > G) carries a 60
percent risk of breast cancer by age 80, has the same penetrance as BRCA2 gene
mutations and is significantly (p = 0.00008) associated with a breast cancer risk (Goldgar,
et al., 2011). This large study (n = 2,570) assessed 76 variants in ATM among participants
included in the NCI sponsored breast cancer registry in New Zealand. Sokolenko, et al.
(2014) aimed to assess double heterozygosity of five hereditary breast cancer gene
mutations (BRCA1, CHEK2, ATM, Nibrin [Nijmegen Breakage syndrome gene] (NBN)
and Bloom syndrome (BLM),) in known breast cancer patients (n = 5931). The
researchers identified 17 double heterozygotes (See Table 2.1) in the sample population,
including CHEK2 and ATM mutations, BRCA1 and ATM mutations, BRCA1 and CHEK2
mutations and some with BRCA1 and BLM mutations. Sokolenko’s results also suggested
that individuals with double heterozygosity in breast cancer predisposition genes tend to
acquire the disease at a younger age (≤50) with a more aggressive phenotype (Sokolenko,
et al., 2014).
Partner and Localizer of BRCA2 (PALB2)
The PALB2 protein is called the ‘partner and localizer of BRCA2’ because it
interacts with BRCA2 and causes a caretaker function (Hartley, et al., 2014; Tischkowitz,
et al., 2012). PALB2 with BRCA2 coordinates DNA stability in nuclear foci (Xia, et al.,
2006) while they interact with BRCA1 (Zhang, et al., 2009). PALB2 is considered to act
like a “bridge” and interacts with BRCA1 and BRCA2 building the BRCA1-PALB2-
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BRCA2 complex (Fernandes, et al., 2014). This complex is extremely important in the
DNA double strand break repair system leading to BRCA2 mediated homologous
recombination repair at the location of damaged DNA (See Table 2.2) (Fernandes, et al.,
2014). If DNA double strand breaks are not repaired, they remain after replication and
create established somatic mutations with uncontrolled proliferation and potential for
cancer development (Fernandes, et al., 2014; Xia, et al., 2006).
According to an Australian population study of women with breast cancer and a
family history of cancer, PALB2 mutations (c.3113G > A) are associated with a high risk
of breast cancer. The risk level of PALB2 mutations (much like ATM mutations) is as
great as BRCA1 and BRCA2 mutations (Southey, et al., 2010). Germline mutations in
PALB2 gene are very rare and account for approximately 1-4 percent of the breast cancer
diagnoses in patients who are not BRCA1/2 carriers (Hartley, et al., 2014).
Rahman, et al. (2006) suggested the germline mutation in PALB2 gene should be
included in the high risk category for development of breast cancer. In his study (n =
923), truncating monoallelic (See Table 2.1) PALB2 mutations were seen in 10 patients
with familial breast cancer. The researchers concluded that individuals with familial
breast cancer and truncating mutations of PALB2 had a 2.3-fold higher risk for
developing breast cancer when compared to the control group with non-familial breast
cancer (Rahman, et al., 2006). In a later population-based study, patients with bilateral
breast cancer (n = 559) were screened and compared to patients with unilateral breast
cancer (n = 565) (Tischkowitz, et al., 2012). The statistical analysis detected significant
(p = 0.04) pathogenic PALB2 mutations in patients with contralateral breast cancer when
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compared to the unilateral control group. These results identify the need for genetic
testing in families who are carriers of the PALB2 germline mutations in order to guide
treatment for clinicians and suggest prevention strategies from further cancer diagnoses
within the families (Tischkowitz, et al., 2012).
Hartley, et al. (2014) studied participants (n = 17) with negative BRCA1/2
mutations and tested them for PALB2 mutations. They detected two deleterious mutations
in two participants who also had a very strong family history of breast cancer. Although
PALB2 mutations are rare in the population, results of this study suggest this gene still
has a critical role in cancer susceptibility (Hartley, et al., 2014). One of the largest cohort
studies in the U.S. assessed 1,479 participants for PALB2 mutations using Sanger
sequencing and quantitative multiplex polymerase chain reaction PCR (See Table 2.1)
(Fernandes, et al., 2014). The participants were divided into two groups; “high risk” and
“low risk” with risk being based on calculations using age at breast cancer onset and
family history of cancer. The sequencing data identified 10 pathogenic mutations (CI =
0.5-1.92) in the high risk group (n = 955) and two mutations (CI = -0.5-1.37) in the low
risk group (n = 524). There were 59 samples with variants of uncertain significance
(VUS) (See Table 2.2). These data suggest a low frequency of PALB2 mutation incidence
in patientts with HBOC (Fernandes, et al., 2014).
Clinical characteristics of breast cancer patients with biallelic (See Table 2.2)
BRCA2 and PALB2 mutations are similar. These genes are part of the Fanconi anemiabreast cancer pathway and are involved in DNA double strand break repair (Adank, van
Mil, Gille, Waisfisz, & Meijers-Heijboer, 2011). These gene mutations also share clinical
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characteristics such as childhood tumors (biallelic), pancreatic cancer (monoallelic) and
female breast cancer (monoallelic) (Adank, et al., 2011).
While several studies reviewed the prevalence of the mutations, Teo, et al. (2013)
looked at the tumor morphology to predict the germline PALB2 mutation in patients with
breast cancer. The researchers compared pathology reports from 28 patients who were
known carriers for the PALB2 mutation with 828 registered breast tumors (both groups
included women who were diagnosed with breast cancer before the age of 60). The
researchers found minimal sclerosis (less than 20 percent) in tumors of the participants
with PALB2 mutations as opposed to BRCA1/2 mutation carriers with extensive sclerosis;
however, there was no identification of significant similar tumor morphology between
PALB2, BRCA1 and BRCA2 mutation carriers. This is intriguing because PALB2, BRCA1
and BRCA2 are all part of the homologous recombination repair complex (See Table 2.2)
(Teo, et al., 2013).
BRCA1 and PALB2 are involved in transcription regulation by co-activation; they
occupy large gene coding regions and are associated with RNA polymerase II (Gardini,
Baillat, Cesaroni, & Shiekhatta, 2014). These genes are also involved in the retinoic acid
signal, an inhibitor signal to tumor growth, so both of the PALB2 and BRCA1 proteins
have critical roles in the regulation of gene expression in growth pathways causing
proliferation (Gardini, et al., 2014). Loss of function mutations are also reported by a
research study published in 2014 that suggests PALB2 mutation carriers have almost the
same frequency as BRCA2 patients and recommends following the same management
strategies as what is suggested for BRCA2 mutation carriers (Antoniou et al., 2014).
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Based on previously mentioned studies, although with limited sample numbers, inclusion
of these new genes in breast cancer genetic testing panels can be beneficial to individuals
considered at high- risk for developing breast cancer.
Conclusion
Clinical genetic testing with multi-gene panels of carriers for ATM and PALB2
gene mutations would be appropriate for the population of individuals considered to be
“high risk” for hereditary breast cancer syndromes, even though the prevalence appears
to be low. According to the genetic testing registry (GTR) at the National Center For
Biotechnology Information (NCBI), there are several clinical genetic testing laboratories
available for breast cancer that include ATM and PALB2 mutations in their multi gene
panel testing (GTR, 2014). Currently, 28 genes are included in NCCN guidelines: APC,
ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2,
EPCA, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50,
RAD51C, RAD51D, RINT1, SMAD4, STK11, TP53 (NCCN, 2015). There are no
standardized recommendations for prevention and/or screening protocols for ATM and
PALB2 mutation carriers. While clinicians also investigate the new research publications
for guidance, many use the NCCN guidelines for genetic testing for significant family
history of breast cancer or diagnosis at a young age (≤50) (NCCN, 2015).
Since most studies with a focus on ATM and PALB2 genes have a low number of
participants, decreasing the statistical power, the findings emphasize the importance of
large studies to assess the variants of ATM and PALB2 genes in order to improve
screening, diagnosis, treatment and disease management. Because different disease
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management strategies are available based on genetic information, genetic testing for all
breast cancer susceptibility genes (not just for BRCA1/2 genes) will guide clinicians to
offer more personalized treatment based on patients’ biomarkers. Healthcare providers
play a critical role in patient care from screening to diagnosis and treatment of breast
cancer. Current knowledge of breast cancer genomics and monitoring the rapidly
changing guidelines for cancer genetics will guide clinicians to accurately offer genetic
testing and implement appropriate strategies to promote better outcomes for breast cancer
patients.
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Table 2.1
Technologies targeting human genomics
Technology
Expression Profiling
by DNA Microarray
Array Comparative
Genomic
Hybridization
Next-Generation
Sequencing
Massive Parallel
Sequencing
Sanger Sequencing

Quantitative
Multiplex Polymerase
Chain Reaction

Application to
Cancer
Prediction of
clinical outcome
Discovery of
variations in DNA
copy number
Genomic profiling
to guide clinical
management
Detection of cancer
of unknown
primary
DNA sequencing
method using DNA
primers
Sequencing
method using PCR
to amplify DNA
sequences at the
same time for large
genomic
rearrangements
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Table 2.2
Definitions
Term
Homologous Recombination
Variants of Uncertain Significance (VUS)
Double Heterozygosity
Monoallelic Truncating Mutation
Biallelic Mutation

Definition
Exchange of similar or same nucleotides to
repair DNA double strand breaks
A variation of genetic sequence with
unknown pathogenic association
One person with two different gene
mutations
Heterozygote (single allele) mutation in
one of three stop codons
Mutation in both alleles (both version of
the same gene)
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CHAPTER THREE
INFLAMMATORY BREAST CANCER
Abstract
(Submitted on 10/07/15, Biological Research for Nursing)
Inflammation is considered to be the first line of defense against tissue injury and
infection. Several chronic diseases such as cancer, arthritis, cardiovascular disease,
obesity, type 2-diabetes and Alzheimer’s disease are associated with inflammation.
Inflammatory breast cancer (IBC) is an uncommon type of breast cancer. Phenotypically
it includes erythema, skin irritation and typically, no discernable tumor. The pattern of
growth is aggressive, with a poor prognosis and low overall survival rate. Clinical
features such as orange peel, swelling and redness diagnose IBC; signs are frequently
mistaken for an abscess or mastitis. The disease is also considered to be genetically
complex and heterogeneous. The purpose of this paper is to describe the evolution of
inflammatory breast cancer, investigate genomic causes of the disease, explain known
disease pathogenesis, evaluate different methods of diagnosis and discuss new
approaches to personalized care through a comprehensive literature review of scholarly
research articles.
Inflammation and Cancer
Inflammation is the first line of defense against injury and infectious factors in the
body and overlaps with the immune system to play a crucial role in some human diseases,
including cancer, diabetes, asthma, allergy, autoimmune disease, neurodegenerative
disease, heart disease and Alzheimer’s disease (Libby, 2007; Vodovotz , Bartels &
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Chang, 2008). Influenced by several mechanisms affected by oxidative stress, injury,
fibrosis and angiogenesis, inflammation is considered to be a protective response that
also involves blood cells (platelets, leukocytes, endothelial cells) and proteins
(Grivennikov, Greten & Karin, 2010; Kajihara, 2011; Libby 2007). The history of
attention to inflammation begins when Aurelius Cornelius Celsus (Roman physician) first
described chronic inflammation with four essential signs: pain (dolor), redness (rubor),
heat (calor) and swelling (tumor) due to changes in perivasculature, hyperemia, increased
blood flow and increased permeability (Libby, 2007; Scott, Khan, Cook, & Duronio,
2004).
Biological stress initiates several pathways and involves several cells, including
macrophages, natural killer cells, mast cells, T- cells, B-cells and dendritic cells (See
Table 3.1) (Libby, 2007; Vodovotz et al., 2010). Acute inflammation is the early reaction
to tissue injury and infection and it is part of the innate immune response that has two
overlapping stages: the cellular stage initiated by leucocytes movement to the affected
area and the vascular stage with increased capillary permeability (Ward, 2010). Both of
these stages along with released chemical mediators, such as chemokines, histamines and
serotonin, to the affected area result in acute inflammation (See Figure 3.1) (Simundic,
2011; Ward, 2010). Macrophages are leukocytes leading the cell-mediated immune
response by ingesting the foreign materials at the site of injury or infection through a
series of chemical and cell interactions (Ward, 2010). Pattern recognition receptors
(PRRs) are secreted by macrophage and (See Table 3.1) identify the initial recognition of
the infection or the injury (Simundic, 2011). Some molecules are also involved in the
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process, such as free radicals and cytokines (Libby, 2007; Vodovotz et al., 2010). The
PRRs sense damage associated molecular patterns (DAMPs) and pathogen associated
molecular patterns (PAMPs) (See Table 3.1). Inflammation initiation begins with pattern
recognition receptors (expressed by macrophages) such as Toll-like receptors and NODlike receptors (See Table 3.1) that perceive DAMPs or PAMPs. These receptors
participate in the activation of signal transduction pathways, signal dependent
transcription factors and eventually activation of the genes promoting inflammation
(Libby, 2007; Tabas & Glass, 2013). Binding of the Toll-like receptors also increases
phagocytosis, cytokine release, lipid mediators and autacoids, which expand the
inflammation response (Hunter, 2012; Libby, 2007; Libby et al., 2010).
The adaptive immune response is slower than the innate response and its
mechanism is more complex requiring several molecular structures (Libby, 2007; Porth,
2011; Simundic, 2011). For example, when antigens are introduced to T-cells, they are
recognized causing T-reg cells to initiate several responses including cytotoxic effects by
T-cells and secretion of an antibody by B-cells. There are two types of differentiated Tcells, T-helper 1 (Th1) cells and T-helper 2 (Th2). The Th1 cells secrete a variety of
cytokines (See Table 3.1) such as interferon-gamma (INF-γ); an important link between
the innate and adaptive immune response pathways. TNF-γ induces macrophage to
produce mediators and pro-inflammatory cytokines. On the other hand, Th2 cells
stimulate the humoral immune response by developing cytokines to induce B-cell
antibody production. Th2 cells can also activate mast cells that lead to chronic
inflammation (See Figure 3.1) (Libby, 2007; Porth, 2011; Simundic, 2011).
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Chronic inflammation lasts longer than acute inflammation and is selfperpetuating. Chronic inflammation is due to immunosuppression and is mediated by
myeloid-derived suppressor cells (MDSCs) and associated with down regulation of the
“cluster of differentiation” 247 (CD247) cells (See Table 3.1) (Baniyash, Sade- Feldman
& Kanterman, 2014). Innate and adaptive immunity’s signals couple and interact into two
types of cells: mesenchymal cells (See Table 3.1) and epithelial cells .The signals induce
leukocytes and eventually lead to chronic inflammation, angiogenesis, cell proliferation,
extracellular remodeling and apoptosis. Th cells are associated with several chronic
inflammations seen in different organs that result in chronic hepatidites, rheumatoid
synovium and atherosclerotic plaques (Grivennikov et al., 2010; Hunter, 2012; Libby,
2007; Libby et al., 2010). In the Th2 type immune response dendritic cells (a type of
macrophage) are exposed to thymic stromal lymphopoietin (See Table 3.1) (Coussens,
Zitvogel & Palucka, 2013). Th2 cells such as CD4+ T-cells produce interleukin (IL) 4 and
IL13, which leads to tumorigenesis, perhaps due to direct tumor development or indirect
tumor development with macrophages (Coussens et al., 2013). The apoptosis pathway
alteration is a possible effect of direct tumor development whereas indirect effects
include pro-angiogenic factors and an alteration of growth factors that cause CD8+ T-cell
proliferation (See Figure 3.1) (Coussens et al., 2013). Moreover, macrophages can
promote malignancy by tumor cell invasion, inflammation, matrix remodeling,
intravasation, angiogenesis and seeding at a distant site (Condeelis & Pollard, 2006).
Inflammation is associated with the four steps of tumorigenesis: initiation,
promotion, invasion and metastasis (Hunter, 2012). It can be the result of infections due
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to Helicobacter pylori (gastric cancer), Hepatitis B or C (hepatocellular carcinoma), gram
negative bacteria such as the Bacteroides (colon cancer) and Schistosoma (bladder
cancer) (Grivennikov, Greten & Karin, 2010). Chronic inflammation is responsible for
20% of all cancers (Grivennikove & Karin, 2011; Mantovani et al., 2008). The Ras
protein is involved in inflammation and plays an important role in ethiopathogenesis of
epithelial ovarian cancer (Liu et al., 2004). IL-1β, IL-6 and tumor necrosis factor α (TNFα) cytokines promote epithelial ovarian cancer (Maccio & Madeddu, 2012) while
expression of the Toll-like receptor-4 gene is associated with colon cancer (Fukata et al.,
2007). Pathophysiology of endometriosis suggests over-expression of several markers
potentially involved in Toll-like receptor dependent inflammation. Both Toll-like
receptors and oxidative stress pathways are activated during the process of the chronic
inflammation (Kajihara et al., 2011).
Inflammatory Breast Cancer
Inflammatory Breast Cancer (IBC) is a very rare type of invasive breast cancer,
accounting for approximately 2.5 percent of new breast cancer diagnoses in the United
States. It has specific features that are different from those of invasive breast cancer with
IBC aggressively developing within a few weeks or months (Fernandez, et al., 2013;
Makower & Sparano, 2013; Robertson, et al., 2010; Shkurnikov, et al, 2013). The most
distinctive physical symptoms include edema, erythema and swelling of the breast with
an overall dimpling that makes the skin appear much like an orange-peel (peau d’
orange). Commonly, no tumor is identifiable via breast or diagnostic examinations. IBC
is frequently characterized by hormone receptor negative status, rapid propagation and
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early metastatic evolution resulting in a poor prognosis (Makower & Sparano, 2013).
Currently, IBC has been described as a distinct entity from other types of breast cancer
and mostly attacks females; however, it has been reported to affect men as well
(Robertson, et al., 2010). The disease regularly occurs in people who are under the age of
50 due to premenopausal carcinogenesis and it is usually misdiagnosed because of its
typical appearance, which includes swelling, erythema and orange peel skin (Fernandez,
et al., 2013).
The incidence of the disease varies among different populations; in Japan, IBC is
responsible for 0.09 to 2.9 percent of all breast cancer diagnoses, whereas Tunisia has an
incidence of 5.7 percent and Egypt an11.1 percent (Dawood, et al., 2011b). Patients who
are diagnosed with IBC have a higher risk of mortality when compared to patients with
non-IBC (non inflammatory breast cancer). This is probably due to the invasive nature of
the disease (Dawood, et al., 2011b). Statistics show that the incidence of this type of
breast cancer is increasing on a global scale (Fernandez, et al., 2013). Patients who have
been diagnosed with IBC have unknown metastases, though many are identified at the
time of diagnosis (Van Laere, et al., 2013). IBC has similar symptoms to diagnoses of
mastitis, erysipelas (a mammary gland inflammatory disease), or abscess and this is the
main concern when it comes to early and proper detection. This can interfere with the
time-to-diagnosis of IBC, as the patient is treated initially with at least a 7-10 day cycle
of antibiotics (Dawood et al., 2010). The extended time could allow the IBC to develop to
the point of metastases since even at the earliest stages this is an extremely fast growing
malignancy (Shkurnikov, et al, 2013).
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In a large population study performed by Dawood, et al. (2011b), breast cancerspecific survival was compared between stages IIIB/C IBC and locally advanced nonIBC (LABC) participants. The statistical analysis revealed a 43% increased risk
(p=0.008) of death for the stage IIIB/C IBC patients as opposed to LABC patients
emphasizing the importance of new and effective treatments to increase participant
outcomes (Dawood, et al., 2011b).
Histological Features of IBC
The majority of patients diagnosed with IBC have estrogen and progesterone
receptor negative (ER/PR negative) and human epidermal growth factor receptor 2
(HER2) negative biomarkers though HER2/neu receptors can also be positive. Like other
types of breast cancer diagnoses, IBC patients with hormone receptor positive tumors
have a better prognosis due to available treatments that target those receptors (Makower
& Sparano, 2013). Other biomarkers are also used for molecular analysis in patients with
IBC such as oncosuppressors genes (e.g., p53) and certain growth factors such as
epidermal growth factors (Shkurnikov, et al, 2013). In a study done by Cairo University,
27 tumors were assessed from patients with IBC and compared with non-IBC tumors.
Women diagnosed with IBC were also diagnosed with at least four positive lymph nodes
(LN) with positive tumor emboli as opposed to non-IBC patients with no positive LNs at
diagnosis (Mohamed, et al., 2014).
The most distinctive physical symptoms are hypothesized to be the result of
dermal lymphatic (very small vessels in dermis) invasion by tumor emboli obstructing the
dermal lymphatic vessels; the clinical symptom of inflammation is initiated by the
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obstruction (Makower & Sparano, 2013; Mohamed, et al., 2014; Tomasevic & Kolarevic,
2012). Tumor emboli are able to cause metastasis and ultimately organ failure—due to
being obstructive, extremely angiogenic and angioinvasive (Tsoi, et al., 2010).
Diagnosis
IBC can be difficult to diagnose and this could be due to a variety of
complications. As previously noted, symptoms of IBC can be confused with the signs of
mastitis as they are both associated with inflammation of the breast tissue (Dawood, et
al., 2011a). Pain and firm breast tissue associated with inflammation makes it difficult to
palpate breast lesions and frequently there is no breast lump that can be palpated or
visualized through the use of technology (Dawood et al.). In addition, many young
women diagnosed with this disease already have dense breast tissue, making it even more
challenging for mammography to identify the presence of the tumor (Dawood, et al.,
2011a).
In 2008, the first international conference on IBC was held and included a panel
of global IBC experts including oncologists, radiologists, surgeons and pathologists
operating in the breast cancer arena. The panel was brought together with the purpose of
designing comprehensive guidelines. A consensus statement was developed based on
their extensive research of the studies focused on IBC. The panel also identified criteria
for the diagnosis and treatment of this aggressive breast cancer, including requirements
for early detection, diagnosis, staging and treatment approaches (Dawood, et al., 2011a;
Van Laere, et al, 2013). The first step in diagnosing IBC, based on the panel of expert
recommendations, suggests checking for required minimum clinical criteria (Dawood, et
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al., 2011). These characteristics may be present for up to six months, cover most of the
breast and be accompanied by other breast abnormalities but without discernable lumps
(Dawood, et al., 2011a). Clinical examinations and tissue biopsy should follow histology
examination and biomarkers. Biomarkers such as hormone receptors and HER2 status
can be evaluated to confirm invasive breast carcinoma and a diagnosis of IBC (Dawood
et al.).
Radiological tests such as ultrasound and Magnetic Resonance Imaging (MRI) are
included to identify breast parenchymal lesions that have not been previously detected by
ultrasound and/or mammography. In some advanced cases, a Computed Tomography
(CT) scan can verify whether the disease has spread to other parts of the body. Positron
Emission Tomography (PET) scan is not recommended for staging of IBC. This is due to
the lack of adequate data to support the necessity and IBC panel recommendations
(Dawood, et al., 2011a; Scotti, et al., 2013).
Ultimately the panel suggested following the American Joint Committee on
Cancer (AJCC) criteria when staging for IBC. This staging categorizes IBC as T4D and
defines IBC as stage IIIB (including some additional qualities not found in stage IIIB) or
higher (Edge & Compron, 2010).
Biomarker evaluation is necessary to confirm the tissue subtype, tumor grade,
ER/PR and HER2/neu status when guiding the type and schedule of systemic
chemotherapy (Dawood, et al., 2011a). Vascular endothelial growth factors (VEGF) such
as VEGF-C, VEGF-D or C-fos-induced growth factor (FIGF) and VEGFR-3 or FmsRelated Tyrosine Kinase 4 (FLT4), responsible for lymphoangiogenesis, angiogenesis,
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vasculogenesis, proliferation and metastasis, are increased in patients with IBC
(Lerebours, et al., 2013; Dawood, et al., 2011a). Other markers, such as the p53 mutation,
have been linked to IBC and associated with resistance to therapy and overall diminished
survival rate (Dawood, et al., 2011a; Gonzales-Angulo, et al., 2004). C-X-C chemokine
receptor type 4 (CXCR4) is a neoangiogenesis mediator associated with upregulation of
VEGF and chemokine (C-C motif) Receptor 7 (CCR7) is associated with differentiation
of T-Cells and enables the disease to spread into lymph nodes (Cabioglu, et al., 2007). A
poor prognosis was found to be associated with the chemokine receptors, CXCR4 and
CCR7; responsible for metastasis (Cabioglu, et al., 2007).
Genomic Investigation of the Cause of IBC
Genome-wide association studies were conducted to address molecular
mechanisms of IBC through expression profiling (Van Laere, et al., 2013). Although
several genes and gene products are found to be associated with IBC, because of the
heterogeneous nature of the disease, clinical diagnosis criteria are required to confirm the
diagnosis. According to National Center for Biochemical Information (NCBI), several
different genes such as: forkhead box P3 (FOXP3), ras homolog gene family member A
(RHOA), ras homolog gene family member C (ARHC) and WNT1 Inducible Signaling
Pathway Protein 3 (WISP3) are responsible for the phenotypic characteristics of the
disease (Van Laere, et al.).
The genomic investigation of the disease using the NCBI database shows that
several different genes and gene products are associated with IBC in humans. Some of
the designated genes are also responsible for other diseases, including different types of
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breast cancer (NCBI, 2014a). The identified gene products participate in different
pathways such as, v-akt murine thymoma viral oncogene homolog 1 (AKT1) that encodes
for serine-threonine protein kinase. This kinase is responsible for regulation of cell
proliferation, cell differentiation and apoptosis. Mutations in AKT1 are also associated
with Proteus syndrome, Cowden disease 6, familial breast cancer, familial colorectal
cancer, neoplasm of the ovary and schizophrenia (NCBI, 2014b).
Cadherin 1, type 1 (CDH1), is a gene from the cadherin super family and encodes
for a calcium dependent protein; a cell-cell adhesion glycoprotein used to keep cellular
structure and prevent the cells from spreading. Mutations that cause a loss of function of
this gene are responsible for invasiveness and metastasis characteristics of several cancer
types (thyroid, colorectal, gastric and ovarian) in addition to breast (NCBI, 2014c).
The Ras homolog family member A (RHOA) is a guanosine triphosphatase (GTP)
enzyme responsible for the regulation of actin cytoskeleton, cell adhesion and
proliferation (Gilbert-Ross, Marcus, & Zhou, 2015; NCBI, 2014d). Cytoskeleton forms
the cells and stabilizes the tissue to avoid cell deformation and migration (Wickstead &
Gull, 2011). The RHOA mutation is associated with oncogenesis of the mammary glands
(Wu, et al., 2010). Its cell matrix adhesion functions are essential for cell stability,
mortality and invasion and if mutated, this results in oncogenesis (Wu, et al., 2010).
FOXP3 is a transcriptional regulator found in the cell nucleus. Over expression of
the FOXP3 gene product is responsible for immune response via the regulatory T-cells
(T-regs) (See Table 3.1) (Nair, et al., 2013). The overexpression is linked to the

48

recurrence of IBC, which means T-regs are increased due to the immune system response
to cancer (Nair, et al., 2013; Zhang & Zhao, 2007).
Pathogenesis
The complex pathophysiology of IBC is the primary reason for the lack of
knowledge about the pathogenicity of this disease. Multiple studies have used in vivo and
in vitro methods to understand the mechanisms and to be able to guide the treatment;
some of them are discussed in this paper.
In a study done by Bieche, et al. (2004), 36 IBC patients were compared to nonIBC women at stage IIb and III. Researchers found genes located on chromosome 6p21
that were upregulated in IBC patients. These upregulated genes were: genes coded for
growth factors including VEGF, IGFBP7, DTR/HB-EGF, EREG, IL6, CCL3/MIP1A,
ANGP2 and CCL5/RANTES; genes coded for transcription factors including EGR1, JUN,
FOS, JUNB, MYCN, SNAIL1 and FOSB; and genes coded for growth factor receptors
ROBO2, TBXA2R and TNFRSF10A/TRAILR1 (Bieche, et al., 2004). This shows the
heterogeneic nature of the disease and indicates why it has been difficult to identify
unique treatment to offer a better prognosis.
Fernandez, et al. (2013) used the triple negative breast cancer (TNBC) cell line
FC-IBC02, originally from an inflammatory breast cancer patient’s pleural effusion
(excess fluid accumulation in the pleural cavity), as a model of IBC. The cells were fullgrown in both non-adherent (for 14 days) and adherent conditions. These cells formed
mammospheres, a mass of mammary gland cells, after 14 days and then the cells were
transferred to regular culture in a suspension of the adhesion molecules E-cadherin,
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TSPAN24 and β-catenin (See Table 3.1). Adhesion molecules are associated with
invasiveness and migration of cancer cells. Cell-to-cell adhesion is very important for cell
stability and if this contact is impaired, cells will have the capability to migrate and
metastasize. FC-IBC02 cells were also injected into severe combined immunodeficiency
(SCID) mice, without functional T-cells and B-cells, for in vivo studies that led to
complete tumor growth (Fernandez, et al., 2013). Xenografts grew rapidly in a
statistically significant manner with the mice showing metastases in LNs and lungs
(Fernandez, et al., 2013). Due to this research a new IBC cell line was developed with the
same biomarkers and gene signature as the original cell collected from pleural effusion of
a patient with IBC. The results from this study, the new IBC cell line with TNBC
features, will allow researchers to conduct more research to understand the disease
pathogenesis and study new treatments for IBC.
Woodward, et al. (2013) compared the gene expression profiles of their samples
from IBC, non-IBC and normal healthy controls matched for ER and HER2 status using
RNA probes. They failed to find statistically significant specific biomarker signatures
(important for understanding the disease and guiding treatment) for IBC when compared
to non-IBC samples (Woodward, et al., 2013).
Macrophages are important in inflammation in breast tumors and have a critical
role in metastasis (Condeelis & Pollard, 2006; Mukhtar, et al., 2011; Pollard, 2008).
Approximately 50% of the IBC tumors contain leukocytes, mainly macrophages and
lymphocytes. The increased number of macrophages in the tumor is consistent with
invasive tumor and poor prognosis (Sica, Allavena, & Mantovani, 2008). Tumor-
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associated macrophages (TAMs) (Sica et al., 2008) are the regulatory factors in the
relationship between cancer and inflammation and also classified as M1, M2 and
regulatory microphages (Mohamed, et al., 2014; Wang, Liang, & Zen, 2014) (See 3.1).
M1 secretes anti- proliferation cytokines whereas M2 secretes cytokines to enhance
proliferation and is activated by the pro-inflammatory components INF-γ and TNF-α.
The M2 usually is in response to interleukin-4 (IL-4) and interleukin-3 (IL-3) (Mohamed
et al., 2014; Wang et al., 2014). The regulatory microphages secrete cytokines to
promote anti-inflammation and cause tumor growth, metastasis and invasion (Mohamed,
et al., 2014). The results from this study indicated a higher number of macrophage
differentiation markers when compared to non-IBC patients; perhaps a useful marker for
the diagnosis of IBC.
Small non-coding RNAs known as microRNAs (miRNAs) are responsible for
deregulation of gene expression. In several cancer types, including breast cancer,
miRNAs are deregulated either by epigenetic changes or genomic alterations. Several
miRNAs are considered to have good prognostic and diagnostic capabilities because they
are seen in tumor tissues and associated with invasiveness in IBC. Moreover, they can be
predictive, which makes miRNAs expression analyses a potentially critical analytic and
prognostic marker for IBC (Lerebours, et al., 2013; Volinia, et al., 2012). Lerebours, et
al. (2013) examined miRNA expression profiles in patients with IBC by screening 804
miRNAs. Deregulation of 13 miRNAs was found in IBC patient samples as opposed to
non-IBC samples. Seven miRNAs were found to be specifically upregulated in the IBC
samples. All miRNAs except for miR-133 were upregulated in IBC patient samples. The
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data obtained from this study were anticipated because of the nature of miRNAs. They
may be a component of either oncogenes or tumor suppressor genes (Lerebours, et al.,
2013).
The FOXP3 protein controls the development, differentiation and function of the
T-regs (Samstein et al., 2012). As noted previously, T-regs are increased in the blood
and tumor microenvironment of patients with cancer because they suppress anti-tumor
activity of the immune system (Facciabene, Motz, & Coukos, 2012). According to the
Genetic Association Database (GAD), FOXP3 is associated with several other disorders
such as vitiligo, Graves’ disease, leukemia, hay fever, asthma, diabetes type 1,
sarcoidosis, juvenile arthritis and celiac disease (GAD, 2014). Nair, et al. (2013)
suggested that over expression of FOXP3 is linked to the recurrence of TNBC in IBC
patients; therefore, the FOXP3 protein could be an immunotherapeutic target against IBC
cells (Nair, et al., 2013).
Metastasis and invasive activity of IBC is related to two signal pathways affected
by the ras homolog family member C (ARHC) and WNT-1 induced secreted protein 3
(WISP3) genes. WISP3 is involved in ARHC expression in IBC cells and these two genes
act together in the aggressive type of IBC (Kleer, et al., 2004). A current assay from a
whole transcriptome analysis performed by researchers Shkurnikov, et al. (2013), found
137 mRNAs that expressed differentially in the tumor tissue samples of the patients with
IBC (17 downregulated and 120 upregulated genes) which shows the necessity of
assessment of regulatory genes involved in the disease pathogenesis and metastasis
(Shkurnikov, et al., 2013). There are three main biological processes directed by a variety
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of genes involved in IBC including: 1) inflammation (ERBB2IP, IGF2, CHST2, CX3CL1,
GRIN2B, IL1RL2, SAA1, SAA2, SAA4 and DEFB131); 2) transcription (SOX8, SOX9,
ETV4, NFIB and MAFG),; 3) chemotaxis (CCL28, CX3CL1, EFNA5, CMTM7, GRIN2B,
IL28A, PROM1 and TSLP). For example, overexpression of the v-erb-b2 avian
erythroblastic leukemia viral oncogene homolog 2 interactive protein (ERBB2IP) gene in
IBC patients is associated with the inhibition of nucleotide-binding oligomerization
domain containing 2 (NOD2) signal pathways. This pathway is responsible for initiation
of inflammation by neutrophils and macrophages. (Shkurinkov, et al., 2013). The study
also found higher expression in CX3CL1 and CCL28 genes responsible for tumors
spreading in cancer patients. IBC expression profiles indicate genes involved in
regulation of signaling transduction processes and transcription processes as well as cell
adhesion, apoptosis and chemotaxis (Shkurinkov, et al.).
Treatment
Management protocols for IBC suggest a multidisciplinary route. The most
common treatment of inflammatory breast cancer continues to be the use of systemic
neoadjuvant chemotherapy (Scotti, et al., 2013). The National Comprehensive Cancer
Network (NCCN) guidelines recommend neoadjuvant chemotherapy for IBC patients
(NCCN Guidelines, 2014). The study done by Gianni, et al. (2010) suggested the addition
of neoadjuvant trastuzumab to the anthracycline-taxane regimen, followed by one year of
treatment with adjuvant trastuzumab. This regimen leads to a better pathologic complete
response (pCR) and an improvement in overall survival rates (Gianni, et al., 2010). ER
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positive women with IBC should also be offered hormonal therapy (Tamoxifen or
aromatase inhibitor) after chemotherapy and a mastectomy (Carlson, et al., 2011).
The treatments followed by immediate surgery and radiation therapy helped to
diminish any remaining tumors (Dawood, et al., 2011a). If the tumor was HER2 positive,
anti-HER2 therapy treatment was suggested with Tamoxifen and aromatase inhibitors by
the IBC panel of experts (Dawood, et al., 2011a). Higher pCR has been reported with the
chemotherapy regimen that includes taxane, trastuzumab and anthracyclines in women
with HER2 positive biomarkers (Makower & Sparano, 2013; NCCN Guidelines, 2014).
Once systemic chemotherapy is completed, traditional breast reconstruction
surgery is not recommended immediately after the mastectomy for IBC patients due to
the necessity of radiation therapy, however, delayed reconstruction is reported in some
research studies (Dawood, et al., 2011a). Radiation therapy follows after surgery in order
to eliminate any remaining tumor cells in the tumor area (Dawood, et al., 2011a; Scotti, et
al, 2013). Women with IBC who were treated with a multimodal approach responded
well to therapy, resulting in longer survival (Dawood, et al., 2011a).
Discussion
The literature reveals that IBC is clinically unique and develops rapidly.
Inflammation is the first line of defense in the body after skin, with several different
mechanisms to protect the body. Cellular and vascular stages and their chemical
mediators such as histamines and chemokines are involved in the inflammation process
(Simundic, 2011; Ward, 2010). Inflammation involved in tumorigenesis and chronic
inflammation is associated with 20% of cancers (Grivennikove & Karin, 2011; Hunter,
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2012; Mantovani et al., 2008). IBC will advance as malignant cells infiltrate the
lymphatic and blood vessels, further enhancing the invasive nature of IBC. A majority of
patients diagnosed with IBC have pathology indicating TNBC, the most aggressive type
of breast cancer. Recent management guidelines suggest an aggressive personalized
approach of multi-modal therapy including several types of neoadjuvant chemotherapy
followed by mastectomy, anti-hormone therapy (for patients with positive hormone
receptors) and radiation therapy (Dawood, et al., 2011a).
The panel of IBC experts suggests standard guidelines for diagnosis, treatment
and patient education regarding their risk factors, prevention and lifestyle changes
(Dawood et al., 2011a). The goal of these guidelines is to improve the survival rate. The
objectives were created to develop and promote physician and patient education as well
as encourage the development of clinical trials and international collaboration on IBC
research (Dawood, et al., 2011a).
The genetic alterations mentioned in this article suggest that IBC has a
heterogeneous and complex nature. Furthermore, it emphasizes the necessity of further
investigation and new personalized drug developments in order to achieve better
prognosis and overall survival rate.
Improving awareness plus educating the general public about the disease
symptoms could offer earlier diagnosis, treatment, follow up and ultimately improve the
prognosis. Further collaborative interdisciplinary studies are needed to decipher the
complex molecular mechanism of IBC. These strategies would also lead to better
prognosis and improved survival rate.
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Table 3.1

Definitions
Term
Macrophages1, 2

Mast Cells or
mastocytes3
Natural killer cells
(NK Cells) 2,4
Dendritic cells 2,4
Toll-like receptors
(TLRs) 5
Cytokines 2,4
Interferon 2,4
T-helper cells 4,5,6
Thymic stromal
lymphopoietin

Myeloid-derived
suppressor cells
(MDSCs) 1
Cluster of
differentiation (CD)
7

Mesenchymal
cells2,4,7

Definition
Type of leukocytes involved in ingestion of foreign
materials, they are activated and deactivated during
inflammation; initiation, maintenance and resolution
Are derived from myeloid stem cells and mediating
allergy reactions and in general, inflammatory
responses
Cytotoxic lymphocytes involved in innate immune
response
Cells that present antigens to T-cells at cell surface
These receptors are involved in innate immunity and
expressed in dendritic cells and macrophages
Small proteins secreted by cells for cell to cell
communication and are responsible for
inflammatory response
Part of cytokines proteins and secreted in response
to pathogens
Involved in adaptive immunity involved in B-cells,
T-cells and macrophages activities
Cytokine proteins involved in T-cell maturation

Myeloid immune cells involved in cancer and
chronic infections
A protocol used to determine cell surface proteins
involved in cell signaling and act like ligands or
receptors (CD1 through CD335)
Stem cells with capability of differentiation to any
cell type

Pattern recognition
receptors (PRRs) by
DNA Microarray 6
Pathogen associated
molecular patterns
(PAMPs) 6
Damage associated
molecular patterns
(DAMPs) 8

The initial recognition of the infection or the injury

NOD-like receptors9

Part of PRRs and associated with innate immune
response
Regulate the immune system and is part of self
check of immune system to avoid unnecessary

Regulatory T-cells
(T-regs) 10

Group of pathogenic molecules that are recognizable
by immune system such as TLRs and PRRs
Initiate immune inflammatory response
(noninfectious)
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E-cadherin 2. 7
TSPAN24 11
β-catenin 12
Tumor associated
macrophage
(TAM)16
M116
M216
Regulatory
macrophages17

immune response
Cell to cell adhesion molecule involved in tissue
development and cancer suppression
Tetraspanin 24 are transmembrane 4 super family
and has an important role in cell adhesion
A protein that regulates cell to cell adhesion and
transcription
Regulatory factors of the link between inflammation
and cancer
M1 macrophage secrete cytokines to inhibit
proliferation
M2 macrophages secrete cytokines to promote
proliferation
Regulate inflammatory response

Sources
1. Baniyash, et al., 2014; 2. Porth, 2011; 3. Jung, et al., 2013; 4. Ward, 2010; 5. Libby,
2007; 6. Simundic, 2011; 7. Chan & Hui, 1988; 8. Krysco, et al., 2011 9. Chen, Shaw,
Kim, & Nuñez, 2009; 10. Nair, et al., 2013; 11. Fernandez, et al., 2013. 12. MacDonald,
Tamai, & He, 2009; 13. Sica, et al., 2008; 14. Fleming & Mosser, 2011.
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Figure 3.1
Inflammation and Cancer: An Overview

Sources
1. Porth, 2011; 2. Ward, 2010; 3. Libby, 2007; 4. Simundic, 2011; 5. Coussens, et al.,
2013; 6. Mohamed, et al., 2014
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CHAPTER FOUR
USE OF PROTECTION MOTIVATION THEORY TO GUIDE PREVENTION
STRATEGIES IN WOMEN WITH BREAST CANCER DIAGNOSIS AND
POSITIVE GENETIC ALTERATION
Abstract
The American Cancer Society and the National Comprehensive Cancer Network
(NCCN) frequently update the guidelines for breast cancer detection, prevention and risk
reduction (American Cancer Society, 2015, NCCN, 2015 a). However, the numbers of
individuals who follow the guidelines are low (less than 0.2% of women in United States
use Tamoxifen and approximately 3% of Australian women follow the prevention
guidelines) (Ralph et al., 2014). The numbers to follow prevention strategies are even
lower in minority ethnicities (American Cancer Society, 2015). In order to improve the
number of individuals who follow the detection, prevention and risk reduction guidelines,
the Protection Motivation Theory (PMT) is applied to identify and promote the use of the
motivators to help individuals to understand and follow the risk management strategies
for breast cancer.
The purpose of this paper is to discuss the components of PMT and how this
theory can be beneficial in breast cancer prevention studies, specifically among different
ethnic groups. A comprehensive review and synthesis of recent literature from scholarly
journals will be used to direct the use of PMT in a suggested pilot study utilizing a focus
group of women with a diagnosis of breast cancer and identified mutation in a
susceptibility gene.
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Purpose
The purpose of the proposed research is to determine if the Protection Motivation
Theory can guide prevention education for women who have a breast cancer diagnosis
plus are positive for a mutation in a susceptibility gene that makes them at higher risk for
another cancer.
Methodology
A focus group research pilot study is suggested to be conducted using high risk
breast cancer patients who have already been diagnosed with breast cancer and completed
genetic testing. The PMT would be used to guide the discussion about experiences with
genetic testing in order to develop prevention education for these women.
Background
Breast cancer is projected to be responsible for 14% of all cancer deaths in the
United States in 2015 (National Cancer Institute [NCI], 2015) with almost 10% of breast
cancer cases associated with germline mutations (Tung et al., 2015). Too many studies to
be counted have been conducted on the topic of breast cancer over the past decade and
with advances in DNA sequencing, progress has been made in cancer screening,
prevention, diagnosis and treatment. The National Comprehensive Cancer Network
(NCCN) guidelines suggest different risk reduction strategies for women with a mutation
in a susceptibility gene including mastectomy, bilateral salpingo oophorectomy and
agents such as estrogen receptor modulators (NCCN, 2015b; Vogel, 2015; Zhang,
Simondsen, & Kolesar, 2012). Although there are several suggested strategies for
reducing breast cancer susceptibility in women at high risk, current use of the procedures
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with or without the agents is very limited (Vogel, 2010; 2015). Disparities and lower
socioeconomic status among different ethnic groups is a challenge for cancer prevention
and screening (American Cancer Society, 2015). The Protection Motivation Theory
(PMT) model is one option that can be applied to the motivation of women at high risk to
participate in prevention and risk reduction protocols.
Protection Motivation Theory
Rogers originally suggested the PMT in 1975 with evolution throughout the years
(See Figure 4.1) (Maddux & Rogers, 1983; Milne, Sheeran, & Orbell, 2000; Rogers,
1975). Based on a social cognitive theory, the PMT describes how fear appraisals impact
behavior (Bui, Mullan, & McCaffery, 2013; Rogers, 1975). Fear and threats are
unpleasant emotions, so any circumstances that induce fear can change behavior and
attitudes specifically if it depends upon an individual’s aim to lessen the emotional
impact of the fear or threat (Maddux & Rogers, 1983). This theory is a very reliable
predictor of the existing behavior but is limited in future prediction (Milne et al., 2000).
The PMT model adapted from Lee et al. (2007) demonstrated two main constructs
of the theory: threat appraisal and coping appraisal. Threat appraisal is threat and fear of
someone’s health status, so interventions can be taken to prevent or lower the impact of
the threat such as health education (e.g., training for women’s self-breast exam) and
screening methods (e.g., mammography); however, it is difficult to initiate interventions
to change health behavior based on fear (Lee et al.). Rogers later suggested coping
appraisal as a better predictor for prevention studies (Maddux & Rogers, 1983; Milne et
al., 2000).
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The PMT consists of series of interrelated concepts: severity of the health
problem, vulnerability or risk of the threat, self-efficacy and response to the protective
measures (See Figure 4.1) (Helmes, 2002). These four concepts of the theory have the
advantage to promote protective behavior when compared to other models, such as the
theory of planned behavior and the health belief model (Ralph et al., 2014). However,
some of variables in the theoretical model are difficult to measure, while other variables
such as severity, susceptibility, self-efficacy and response efficacy are well defined
(Milne et al., 2000). The characteristics of this theory make it suitable for research studies
related to health and well-being of individuals who could benefit from its application in
clinical practice and patient care.
Research, PMT and Practice
Research on using PMT and its constructs has been conducted in different topics
of health-related issues. Grindley et al. (2008) focused on physical activity and exercise
using PMT to predict adherence to rehabilitation programs. They used PMT as a
screening tool for patients who are suffering from orthopedic disorders; fear resulted
from mobility complications, pain and also prescribed rehabilitations. The study found
that using the PMT model in their screening tool could help clinicians to find out if their
patient was at higher risk of poor adherence (Grindley, Zizzi, & Nasypany, 2008).
A skin cancer screening tool based on PMT was used in a research study focusing
on patient education of skin cancer prevention strategies such as using sunscreen and
avoiding tanning beds (Baghianimoghadam,, Mohammadi, Noorbala, & Mahmoodabad,
2011). The PMT was also used by Katz et al. (2009) to create an educational video for
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colorectal cancer screening. The training video was evaluated and suggested changes to
some of the components of the video were made in order to help patients better follow the
guidelines for screening (Katz et al.).
Helms (2002) applied PMT and its components (See Figure 4.1) to discuss the
predictors of intention and motivation of women to consider breast cancer genetic testing.
The study found that women who were more worried about breast cancer (perceived risk)
believed it is an advantage to go forward with genetic testing and wanted to take benefit
of testing for an inherited mutation. This theory helped Helms to determine the important
factors in decision-making in regard to genetic testing for mutations in women at low or
moderate risk for breast cancer (Helms, 2002).
Another group of researchers looked at the effect of personalized genetic risk
information on perceived efficacy of the helpfulness of the prevention, early detection
and treatment protocols (Collins, Wright, & Marteau, 2011). They systematically
reviewed studies that assessed the effectiveness of genetic risk information on changing
health behavior (obesity, heart disease, diabetes and depression). Of the 5 (out of 1340)
selected articles reviewed, only one study showed effective results on perceived
effectiveness of medical intervention in terms of personalized genetic information
(Collins et al.). On the other hand, patients who have done obesity risk check, showed
intention to initiate a healthy lifestyle when they understood their high risk of becoming
obese or overweight by using PMT for intention to change behavior (Frosch, Mello, &
Lerman, 2005). This intention for behavioral change in patients indicates the importance
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of perceived behavioral control and intention to change risky habits based on their
genetic susceptibility to obesity (Fosch et al.).
PMT and Breast Cancer Screening/Prevention
The American Cancer Society (ACS) predicts 231,840 new cases of invasive
breast cancer and 60,290 cases of breast carcinoma in situ to be diagnosed in 2015
(American Cancer Society, 2015). According to the American Cancer Society, the lower
the socioeconomic status, the higher the breast cancer mortality; this is regardless of race.
The ACS also reported that individuals with 12 or fewer years of education tend to have
triple the mortality rate compared to those with higher levels of education (American
Cancer Society, 2015). Their results also indicated that cancer mortality rates in nonHispanic black individuals are higher than in other ethnic groups; disparities are due to
lack of high-quality prevention, diagnosis and treatment services (American Cancer
Society, 2015).
A large number of women, mostly from minority ethnicities (African American,
Hispanic and Asian women), do not return for their mammography screening as
suggested by guidelines even though these women are at higher risk to be diagnosed with
advanced breast cancer and an earlier age at death (Moy, Park, Feibelmann, Chiang, &
Weissman, 2006). Moy et al. (2006) recruited 49 participants from minority ethnicities
(14 Hispanic, 16 African American and 19 Asian) for the study. Results indicated African
Americans and Asians women believed that insurance would not be a barrier to their
return for mammography screenings. A few of the 16 African American women believed
that screening methods would lead to breast cancer and cause death (fatalism); they
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preferred to avoid the prevention strategy due to their health beliefs, as it was stated by
Asian and Hispanic women as well (Moy et al., 2006).
Estrogen modulators (e.g., nalvodex and raloxifene) and aromatase inhibitors
(e.g., exemestane and anastrazole) are other options for eligible women to use as risk
reduction medications (NCCN, 2015b; Vogel, 2015). However, research reveals the
interest and adherence to use the medications are low (0.2% of eligible high risk
individuals in the United States and 3% in Australia) (Karmakar, 2013; Ralph et al.,
2014). According to Karmakar, 38% of participants (n= 145) who had physician orders
for adjuvant therapy were non-adherent to their aromatase inhibitors. The study sent
questionnaires to the participants that were established based on PMT. Protection
motivation scores showed significant correlation to adherence (r=0.31), but coping
appraisal was a better predictor of adherence to aromatase inhibitors compared to threat
appraisal in this study (Karmakar, 2013).
Based on the above discussion, the best approach would be an intervention using
a prevention model based on PMT to educate and encourage women to follow the
screening guidelines. The PMT, as mentioned earlier, consists of two cognitive processes,
threat appraisal and coping appraisal, which lead to intention to change health behavior
(Bui et al., 2013; Helms, 2002) and is used to develop and suggest this study.

Methods
Design and study samples
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This is a focus group research pilot study applying constructs and concepts of
Roger’s (1975) PMT to educate and urge women with breast cancer to follow the
strategies to prevent second primaries. According to several research studies, not all
women adhere to the guidelines (ACS, 2015; Bui et al., 2013; Karmakar, 2013; Lee et al.,
2007; Moy et al., 2006; Ralph et al., 2014; Vogel, 2015).
This study will invite 10 women with breast cancer and a positive mutation in
hereditary breast cancer genes to a focus group meeting. They will be interviewed based
on questions that applied PMT to assess their intention to change health behavior based
on the genetic test results. The participants will learn about the study by a phone call
contact by principle investigators of this study.
Instruments
PMT has been used in several studies (Cyrus-David, & Strom, 2001; Helms,
2002; Lee et al., 2007; Morrison et al., 2010; Ralph et al., 2014). Based on these research
studies, this pilot study is suggested. The results from this pilot study focus group, which
is based on interview questions using PMT, would assist us to develop prevention
education for women with breast cancer who are at high risk for hereditary breast cancer
syndromes.
The following measures will be used based on specific aims of the study:
•

Participant demographics to include age, race, ethnicity, insurance, level of
education, body mass index (BMI) and physical activity level (due to their
associations with breast cancer risk).
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•

Family history of cancer is very important to determine their risk percentage
based on NCCN guidelines/ Genetic/Familial High Risk Assessment: Breast and
Ovarian.

•

Interview questions based on each of PMT constructs:
o Perceived risk measure can be taken by asking these questions:
§

Severity (Helms, 2002):
•

How serious do you feel you may be diagnosed with
another type of cancer based on your high risk status?

•

How severe you think your disease outcome will be based
on your genetic testing result?

§

Vulnerability (Helms, 2002; Lee et al., 2007)
•

What is the likelihood that you will be diagnosed with
another cancer?

•

What are the chances a new cancer diagnosis would be due
to your genetic mutation(s)?

•

Explain if you can control or prevent it from happening.

o Perceived coping can be measured by following questions:
§

Response efficacy
•

Describe what genetic testing revealed about your health
and well-being

•

State different strategies and explain how following the
guidelines would change your risks?
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•

Discuss if you think adapting a healthy lifestyle would
lower your risk of a secondary cancer?

§

Self-efficacy (Helms, 2002; Lee et al., 2007)
•

Identify your personal cancer risk factors.

•

Discuss the actions you might take to reduce your risk.

•

Provide examples of risk reduction strategies you might
use.

•

Would you prefer to have educational materials, clinician
recommendations, or both?

o Participants’ intention to change their behavior also can be assessed by the
following question (Cyrus-David, & Strom, 2001; Helms, 2002; Lee et al.,
2007):
§

How likely are you to take the prevention actions?

§

How much interest do you have to take action?

§

Discuss how the genetic testing would/could help you decide?

§

Explain if your decision would be changed if you did not have
genetic testing?

§

How likely are you to recommend genetic testing to your friends
and family?

Human subjects and research approval procedures
Prior to development of the study and interview questions, the study protocol will
be reviewed by the Clemson University Institutional Review Board (IRB) to receive
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approval. An informed consent is also developed and will be evaluated by IRB to explain
the details about the purpose of the study, risks and potential benefits for participants to
assess, ask questions and sign before the focus group meeting. All participants will be
invited by study principal investigators and will be informed about the purpose of the
study before scheduling the meeting.
Data collection procedures and data analysis
The total number of 10 participants will be invited to the study from a cancer
clinic in Southeast region by study principal investigator, an advanced practitioner and
genetic counselor. All invited participants will be informed about the details of the study
and will be scheduled for a meeting at the cancer center.
At the focus group meeting, study coordinators will explain the study in details
and consent form will be obtained from each participant. Each participant should be
assigned with identification number following HIPPA regulations with no identifier and
interview questions will be asked and all the answers would be recorded in paper. After
the focus group meeting, participants’ demographics and family history will be collected
from their medical record. All data will be kept in password-protected computers.
The interview responses would be coded and transcribed in order to perform
qualitative data analysis. All coded schemes should reflect the study purpose for intention
to change a health behavior based on PMT application.
Limitations
This is a suggested focus group pilot and researchers are not able to determine
limitations to the study.
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Summary
Based on the review of the articles and examination of several studies using the
PMT, it is concluded that this theory could be useful in today’s research. The growing
knowledge and evidence in practice makes healthcare genetics in breast cancer research
important to reach the goal of personalized medicine with interdisciplinary research
studies in collaboration with different disciplines and institutions.
The more rigorous attempt to create educational materials and deliver the
designed questionnaire should be helpful and effective to encourage women to take the
prevention and screening measures, as it was significant in the Ralph et al. (2014) study.
However, there are limitations to this developing study, including a small sample size in
terms of participants from different ethnic background and a lack of consistency in the
population selection. These limitations make it harder to represent the population
specifically and to generalize when it comes to minority races and ethnic groups. A
further study with consideration of eliminating our limitations is suggested.
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Figure 4.1.
Protection Motivation Theory

Figure 4.1. Protection Motivation Theory model illustrates two main constructs of the
model and how they are interrelated to the main concepts, which eventually lead to
intention to change a health behavior. Adapted from” The development of an arm
activity survey for breast cancer survivors using the Protection Motivation Theory”
by Lee, T. S., Kilbreath, S. L., Sullivan, G., Refshauge, K. M., & Beith, J. M.
(2007). BMC Cancer, 7(1), p.2.
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CHAPTER FIVE
ASSOCIATIONS BETWEEN HEREDITARY BREAST CANCER SUSCEPTIBILITY
GENE ALTERATIONS AND AGGRESSIVE TUMOR PHENOTYPE
IN WOMEN DIAGNOSED WITH BREAST CANCER
Abstract
Purpose
The purpose of this study is to evaluate whether there is an association between
breast cancer susceptibility gene alterations (GA) and aggressive tumor phenotypes using
the molecular biomarkers of breast cancer. The specific variants will also be analyzed to
determine if there is an association with the more aggressive tumors and their markers
among ethnic groups.
Introduction
Almost 10% of 200,000 (approximately 20,000) of predicted new cases of
invasive breast cancer are due to germline mutations, now including at least five newly
identified breast cancer susceptibility gene mutations, such as BRCA1 and BRCA2
(American Cancer society, 2015; Tung et al., 2015). Technological advances in human
genomics, in combination with faster and less costly results, have enhanced the research
for the advancement of targeted therapy of molecular biomarkers (Grada, & Weinbrecht,
2013; Hawthorn, Luce, Stei, & Rothschild, 2010; Staren et al., 2014). Some of these new
technologies require highly trained professionals to analyze the data, but may also have
limitations for their usage such as inaccurate sequencing results and massive data analysis
that can be difficult to manage (Grada, & Weinbrecht, 2013; Previati et al., 2013).

89

Integration of genetic information using new technologies is becoming essential
in order to anticipate a problem, leading to earlier and potentially more specific detection
of breast cancer. Newer technologies such as next generation sequencing (NGS) have
recently been incorporated for oncology genetic multi-panel testing, however, as the
guidelines are now used not everyone would be eligible for these tests. Multi-panel
genetic testing offers the capacity to identify more than BRCA gene mutations in high risk
populations thus providing future options for prevention and early detection of cancer in
more than one generation of patients.
Background and Significance
A comprehensive literature search was conducted using specific search terms,
including “breast cancer”, “high risk breast cancer”, “cancer genetics”, “breast cancer
genes”, “breast cancer genomics”, aggressive breast cancer”, “triple negative breast
cancer” and “hereditary breast cancer syndromes”. Database searches included PubMed,
Google scholar, CINAL, Proquest Nursing and Allied Health, Cochrane's database and
Web of Science. A total of 457 articles were identified between the years 2009 and
2015.The articles were screened for overlap between databases, quantitative versus
qualitative research studies and relevance to specific aims of the research study described
in this chapter. Original research articles with a focus on genes associated with
hereditary breast cancer syndromes and their variants as well as molecular pathways and
pathogenesis were included in the final number. Excluded were articles that were not in
English, papers not related to breast cancer, research articles with lack of evidence and
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animal studies. Finally, there were 44 studies identified having relevance to the purpose
of the project.
The variables in this research study were chosen based on several essentials
including risk factors for having a GA, elements associated with increased risk of breast
cancer and endogenous factors affecting breast cancer. Commonly found factors of
having a mutation associated with a hereditary breast cancer syndrome include: 1) family
history of breast cancer with close blood relatives (three generations) who are diagnosed
at younger age (under the age of 50) or at least two blood relatives diagnosed with breast
cancer at any age; 2) one close family member with ovarian cancer; or 3) two blood
relatives with pancreatic cancer (NCCN, 2015a).
Risk factors related with increased risk of developing breast cancer: 1) early onset
menses; 2) late menopause; 3) increased breast density; 4) advancing age; 5) use of
hormone replacement therapy; 6) having their first child after age 30; 7) higher body
mass index (BMI); 7) history of radiation therapy to the chest, this can include thyroid
cancer and acne radiation therapy; 8) low levels of physical activity; 9) poor nutrition;
10) smoking; or 11) alcohol consumption (with increased breast cancer risk of 10%)
greater than one drink per day (Catsburg, Miller, & Rohan, 2014; Kushi et al., 2012; Li,
2009). Age similarly plays an important role in breast cancer development through
mutation accumulation and decreased DNA damage repair. Estrogen Receptor (ER)
positive breast cancer incidence increases with age as opposed to Estrogen Receptor (ER)
negative cases, which are common in younger women (Gail, Anderson, Garcia-Closas, &
Sherman, 2007). Patients between ages 80 and 85 have 15 times a greater risk of
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experiencing breast cancer compared to younger women. This could be due to the
increased risk of acquired mutations caused by defective DNA damage repair that occurs
as a woman ages (Gail, et al.). DNA double break damage repair decreases as a woman
ages; however, the mechanism remains unknown (Garm, et al., 2013).
Importantly, several recent studies revealed a link between aggressive tumor
phenotypes and hereditary GAs in different cancer syndromes (Castro et al., 2013; Maier
et al., 2014; Pern et al., 2012). BRCA1 and BRCA2 mutations in males have shown a
more aggressive prostate cancer phenotype (Castro et al., 2013;Maier et al., 2014) and
some patients with triple negative breast cancer, considered to be an aggressive
phenotype, were found to have mutations not only in BRCA and, BRCA2 but also the
lesser known genes such as PALB2 and BRD7 genes (Pern et al., 2012).
Purpose of the Study
The purpose of this study was to:
1. Determine if identified breast cancer susceptibility GAs are associated with an
aggressive tumor phenotype in women with a new diagnosis of breast cancer
2. Determine if the aggressive breast cancer tumor phenotype is associated with a
specific gene variant(s)
Methods
This section focuses on the study subjects, procedures, hypotheses and the detail
of the methods.
Subjects
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A total of 257 electronic charts from women with newly diagnosed breast cancer who
had also received genetic testing and counseling between October 2014 and August, 2015
were screened from Bon Secours St. Francis Hospital Cancer Center for study eligibility.
Eligibility included women between the ages of 20 and 90 from diverse cultural and
socioeconomic backgrounds, with and without insurance coverage. Non-eligibility
included women with previously known breast cancer mutation(s), a diagnosis of lobular
carcinoma in situ (LCIS) and benign breast biopsies. After meeting eligibility
requirements, 101 women were invited to participate and determined to be interested in
the study. These 101 participants have an elevated risk to carry a breast cancer
susceptibility gene (based on NCCN guidelines, See Figure 5.1) and received genetic
testing.
Power analysis was performed during the study design using G*Power 3.1 program to
determine how many participants to include in the study (Faul, Erdfelder, Buchner, &
Lang, 2009). The result from the power analysis indicated minimum sample size of 88 to
conduct the study with 0.80 power and alpha of .05.
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Figure 5.1
Hereditary Breast And Ovarian Cancer Eligibility Guidelines

Note. adapted from NCCN Guidelines, 2015a. Genetic/Familial High Risk Assessment:
Breast and Ovarian. Version 2.
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Procedures
Bon Secours St. Francis Hospital Cancer Center provided access to participants
and an office with availability of the electronic health record for data collection. To
promote collaboration and to clarify questions, the study protocol was presented to
surgical, medical and radiation oncologists at a weekly tumor board meeting. The IRB
approved consent form and protocol was also provided and an opportunity for questions
and discussion was offered. An educational luncheon was used to educate all cancer
clinic staff about the purpose of the study and the protocol. An opportunity for discussion
was encouraged in order to make certain the best strategy was identified for participant
accrual. IRB approved flyers to advertise the study were posted throughout the Cancer
Center and distributed within the patient waiting areas.
Electronic health records of potential eligible participants (based on NCCN
Guidelines) were reviewed and logged in a secure file. Participants were invited to join
the study while at the Cancer Center for the genetics appointment or an oncologist clinic
visit. If patients were not scheduled for genetic counseling, each medical oncologist was
approached and asked to inform potential patients on the schedule for that day about the
research study and to grant permission to meet with the team to introduce and explain the
study. After obtaining verbal interest from the patients, the IRB approved consent
(Appendix A-C) form was reviewed with the participant, questions answered and
participant’s signature obtained. To ensure participant confidentiality, a secure log was
created in Dropbox. Each participant was assigned an ID number with no personal
identifiers according to HIPPA regulations.
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A 10-milliliter blood sample was collected from each participant, per protocol.
Labeled vials of blood samples and a completed request form for genetic testing were
transferred weekly to the laboratory facility for test completion. Samples were prepared
for sequencing and identification of mutations. These included the APC, ATM, BARD1,
BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p14ARF and p16INK4a),
CHEK2, EPCAM (large rearrangements only), MLH1, MRE11A, MSH2, MSH6, MUTYH,
NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, SMAD4, STK11 and
TP53 (NCCN, 2015b).
Technicians at the Greenwood Genetic Center performed the laboratory work. This
included all the design and validation of the targeted NGS panel, NGS testing, plus
bioinformatics review and resulting of the specimens. The NGS panel was performed
using amplification based capture methodology (Wafergen, Inc.). Samples were
multiplexed on the on MiSeq instrument (Illumina, Inc.). Bioinformatics experts
validated the pathogenic sequence alterations and variants of uncertain significance using
various databases. These databases included: National Center for Biotechnology
Information (NCBI); ClinVar, cBioPortal of Cancer Genomics; Breast Cancer
Information Core (BIC); Clinical Genome Resource (ClinGen); BRCA Mutation
Database; and Breast Cancer genes IARC (International Agency for Research on Cancer)
database.
The study also collected data from commercial genetic laboratories. Most of the
participants previously had genetic testing done at a commercial laboratory.
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Hard copy data collection sheets (Appendix D) were developed to record the study
data for each participant. These hard copy data were coded for SPSS analysis and then
transferred to an excel spreadsheet. To assure all data were correctly coded and included
for analysis, coding errors were checked three times by two different researchers using
comparison of the paper data collection sheet with the electronic medical records as well
as for accuracy of transference from hard copy to excel spreadsheet.
Data analysis
SPSS® version 22 was used for data analysis. Descriptive analysis was performed
for the participants (N=101) in order to explore the missing data. A table of descriptive
data provided information regarding skewness and standard error; appropriate
transformations were made to correct for skew. Data were cleaned with careful
consideration for errors such as coding and outlier datum.
In order to examine the aims of the study, some variables were combined to form
new variable clusters such as “GAs”, “triple negative breast cancer (TNBC)”, “aggressive
phenotype” and “high-grade tumors”. GAs were defined as either having a positive
genetic mutation or a variant of unknown significance (VUS); the TNBC variable was
computed as negative status for all three tumor markers: estrogen receptors (ER),
progesterone receptors (PR) and human epidermal growth factor 2 (HER2); high-grade
tumors were computed as having grade 3 tumors in either breast tumor sites (right or
left); and, the aggressive tumor phenotype described a TNBC tumor or a high-grade
tumor.
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Associations between the variables were investigated by observing Pearson ‘s
Chi-Square or Fisher’s Exact tests. For this statistical model, GA and aggressive tumor
phenotype were assessed as well as other variables such as: age; ethnicity; insurance
type; BMI; tumor markers (ER, PR, HER2 status); menopausal status; TNBC; and highgrade tumors. The bootstrapping method was used to estimate the population distribution
based on resampling method.
A linear regression model was used to evaluate if the presence of a GA could
predict aggressive breast cancer tumor phenotype. The data were also analyzed with
regression analysis for other variables including age, ethnicity, insurance type, BMI,
tumor markers, TNBC, menopausal status and high-grade tumors.
Results
The results section includes presentation of the descriptive statistics of the
demographic variables followed by an exploration of the study variables. Relationships
between the variables of interest are explored by Chi-Square or Fisher’s exact tests and
predictive measures are evaluated by linear regression model. Linear regression model is
also used to evaluate if a GA predicts an aggressive breast cancer phenotype.
Participants
This section presents the demographic information of the data used for analysis,
followed by the descriptive statistics of the study variables.
Demographic Information
A summary of demographic variables for participants enrolled in the study of
associations between GA and aggressive breast cancer phenotype (N= 101) is presented
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in Table 5.1. The demographics include: age, ethnicity, insurance type, BMI and level of
education. Almost 80% of participants were white, 29.7% had 15 or more years of
education and 37.6% were obese. Of the 101 participants enrolled on the study 67.3%
had private insurance.
Clinical, pathological, and histological status of participant’s tumors are shown in
Table 5.2. Only 8.2% of the participant tumors were identified as TNBC while 26.7% of
the TNBC were identified with high-grade tumors. Table 5.2 also shows 84.5% of the
participants were found to have ER positive and 63.9% to have PR positive tumors. Only
23.7% of participants were diagnosed with HER2 positive tumors.
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Table 5.1
Summary of Demographic Variables for 101 Women
Enrolled in the Study
Frequency Percent
Age
30 – 39
15
14.9
40 – 49
26
25.7
50 – 59
33
32.7
60 – 69
15
14.9
70 and older
12
11.5
Race/Ethnicity
White
Non-White

81
20

80.2
19.8

Insurance Type
Private
Medicare
Medicaid

67.3
21.8
10.9

67.3
21.8
10.9

Education
9 – 12 Years
13 – 14 Years
15 or More

29
42
30

28.7
41.6
29.7

BMI
≤ 24.9(Normal Weight)
29
28.7
25.0 – 29.9(Overweight)
34
33.7
≥ 30.0(Obese)
38
37.6
Note. This table shows descriptive detail of study participants.
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Table 5.2
Data On Clinical, Histological, Pathological Status Of Tumors From 101 Women
Enrolled In The Study
Parameters

Numbers (%)

Low-Grade
Intermediate-Grade
High-Grade
N/A

33.3%
36.4%
26.7%
3.6%

Negative
Positive

15.5%
84.5%

Negative
Positive
N/A

35.1%
63.9%
1%

Negative
Positive
N/A

63.9%
23.7%
12.4%

Negative
Positive

73.5%
26.5%

No
Yes

91.8%
8.2%

Histology

ER

PR

HER2

Sentinel
Lymph Node

TNBC

Note. ER= estrogen receptor; PR= progesterone receptor; HER2=Human epidermal growth factor 2;
TNBC- triple negative breast cancer; N/A- Not available.
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Research Purpose and Hypotheses
The research purpose (RP) and its corresponding hypotheses (H) for this study are
as follows:
RP 1: Determine if breast cancer susceptibility GAs are associated with an
aggressive tumor phenotype in women with a new diagnosis of breast cancer and to
assess if the GA is predictive of an aggressive phenotype.
H0 1: There is no significant association between breast cancer susceptibility GAs
and aggressive tumor phenotypes in women with a new diagnosis of breast cancer
and the genetic variant does not predict an aggressive phenotype.
HA 1: There is a significant association between breast cancer susceptibility GAs
and aggressive tumor phenotypes in women with a new diagnosis of breast cancer or
the GA predicts an aggressive phenotype.
RP 2: Determine if the aggressive breast cancer tumor phenotype is associated with
a specific gene variant.
H0 2: There is no significant relationship between the aggressive breast cancer
tumor phenotype and a specific gene variant.
HA 2: There is a significant relationship between the aggressive breast cancer
tumor phenotype and a specific gene variant.
Description of Study Variables
The study variables of interest were breast cancer susceptibility GAs as identified
by the NCCN Breast and Ovarian Cancer Genetic Assessment guidelines (NCCN,
v2.2015b, page 29) and aggressive tumor phenotype according to molecular subtype of
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breast cancer (Castro et al., 2013; Maier et al., 2014; Pern et al., 2012). Identified breast
cancer susceptibility GAs used for analysis in the study were retrieved from GGC or
commercial results. These DNA changes can be a mutation or VUS identified in any of
the panel genes. The aggressive phenotype was defined as either TNBC or high-grade
tumor (left or right breast).
Only 65 samples (N=101) included complete genetic results for the mutation
analyses. All GGC results were from panel studies while 56.2% of commercial genetic
testing results were from two-gene BRCA analysis and 43.6% from panel testing. The
commercial lab testing decision was based on insurance reimbursement guidelines.
Additionally, 66.7% of VUSs were detected using panel testing compared to 33.3%
VUSs identified from two-gene BRCA analyses. This demonstrates that panel testing has
the potential to reveal more variant results compared to gene specific analyses.
The TNBC and high-grade tumor data were analyzed separately to determine if
associations existed among those variables and germline mutations. In a separate analysis
using Chi-Square or Fisher’s exact tests TNBC associations with GA (mutation and/or
VUS) were assessed as well as linear regression analysis to see if GAs (mutation and/or
VUS) predict TNBC. The same analyses were used for high-grade tumors and GAs to
evaluate the association. They were also measured to evaluate if GAs in high risk breast
cancer susceptibility genes could predict high-grade tumors in women with a breast
cancer diagnosis.
Table 5.3 shows a summary of the study variables. For those with breast cancer
susceptibility GAs, Table 5.4 shows the variety of gene names and variants identified in
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the germline of study participants compared to the family history of hereditary breast and
ovarian cancer syndromes in participants with a positive mutation or VUS result from
genetic testing. Participant #58 has three VUSs (SMAD4 c.606C>, PALB2 c.1641C>T,
PALB2 c.2256A>G) and no family history indicated while participant #61 has two
genetic mutations (BRCA2: c.6024G>C and BRCA2: c. 6252G>C) with a family history
of breast, prostate and colorectal cancer. Participants #28 and #39, both with APC VUSs,
have family history of colorectal cancer as well as breast cancer. Participant #70 has a
mutation of BRCA2 c.5621_5624delTTAA with a family history of breast and ovarian
cancer. Two participants had a family history of pancreatic cancer: participant #66 with
two VUSs (BRCA1: c.736T>G and APC: c.4905G>A) while participant # 96 was
identified to have only one VUS in RAD51C: c.146C>T.
The results from Table 5.4 show the heterogeneous nature of breast cancer in
population of women at high risk for hereditary breast and ovarian cancer. The data
strongly suggest the importance of using a breast cancer panel for genetic testing, but also
the need for assessing family history of other cancers such as pancreatic cancer (e.g.,
participants #96 and #66) and colorectal cancer (e.g., participants #61, #28 and #39) in
conjunction with breast cancer history. These results also suggest that performing larger,
more diverse testing panels than only breast cancer panels for these women may be
essential for patient care and incorporation of personalized medicine for early detection
and/or prevention of second primary breast cancers and other cancers for their family
members.
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Table 5.3
Summary of the Analysis of Susceptibility GAs and Aggressive
Phenotype
Frequency Percent
GAs (mutation &/or VUS)
No
51
49
Yes
18
17
Aggressive Phenotype
No
Yes

66
31

68
32

Note. There were 65 complete GAs data samples out of 101 participants.
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Table 5.4
Family History Of Hereditary Breast And Ovarian Cancer Syndromes In Participants With A GA Result
From Genetic Testing
ID- Numbers
Genetic Testing
Family History of HBOC and Other
Common Cancers
Commercial Mutation
#20
Breast cancer
BRCA2: 4355del4
#31
PALB2: c.172_175del
Breast, ovarian, CRC and other GI
#41
CHEK2: c.1265del
Breast, ovarian, prostate and CRC
#47
BRCA1: c.5319dupC
Prostate and gastric cancer
#51
ATM
Breast and uterine cancer
#61
BRCA2: c.6024G>C
Breast, prostate and CRC
#61
BRCA2: c. 6252G>C
Breast, prostate and CRC
#70
BRCA2 c.5621_5624delTTAA
Breast and ovarian cancer
#87
BRCA1 c. 4035delA
Ovarian, prostate and gastric cancer
#90
Commercial VUS
#21
PMS2: c.2317A>G
Breast and brain cancer
#23
BRIP: c.550G>T
Breast and gastric cancer
#31
ATM: c.6919C>T
Breast, ovarian, CRC and other GI
#32
MSH6: c.3961A>G
Breast cancer and sarcoma
#51
ATM
Breast and uterine cancer
#94
Breast
and thyroid cancer
BRCA2: c. 714_716dup
#96
RAD51C: c.146C>T
Pancreatic cancer
#106
BRCA1: p.E755K
Breast cancer
#118
BRCA1: p.E755K
None

#29
#47

GGC Mutation Type
PTEN c. 1176delT
BRCA1: c.5382dupC

None
Prostate and gastric cancer

#21
#22
#27
#28
#39
#41
#58
#58
#58
#66
#66

GGC VUS
PMS2: c.2317A>G
CDH1: c.892G>A
BRCA1: c. 4039A>G
APC: c. 7514G>A
APC: c.6921G>A
MLH1: c. 2252A>G
SMAD4: c.606C>
PALB2: c.1641C>T
PALB2: c.2256A>G
BRCA1: c.736T>G
APC: c.4905G>A

Breast and brain cancer
Prostate and CRC
Breast cancer
Breast and CRC
Breast, prostate, CRC and uterine cancer
Breast, ovarian, prostate and CRC
None
None
None
Pancreatic cancer
Pancreatic cancer

Note. Participants are identified by study number with their GA (mutation &/or VUS), and family history
of cancer including hereditary breast and ovarian cancer syndrome-cancers, colorectal cancer (CRC),
Gastrointestinal (GI), variant of unknown significant. c. = coding DNA, p. = protein sequence.
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Statistical Results
For Hypothesis 1 and 2, non-parametric Chi-Square and Fisher’s Exact analyses
as well as linear regression model were used to observe the association between breast
cancer susceptibility GAs and aggressive tumor phenotype according to molecular
subtype of breast cancer.
Research Hypothesis 1
Hypothesis one seeks to determine if breast cancer susceptibility GAs are
associated with an aggressive tumor phenotype in women with a new diagnosis of breast
cancer. To assess this question, a Pearson's chi-square test was used to explore the
association between breast cancer susceptibility GAs with an aggressive tumor phenotype
in women with a new diagnosis of breast cancer. Results of the Fisher’s Exact test
showed that breast cancer susceptibility GAs were not associated with an aggressive
tumor phenotype in women in this study with a new diagnosis of breast cancer, χ2(1) =
2.33, p = 0.1. Therefore, the null hypothesis is retained, concluding that there is no
significant association between breast cancer susceptibility GAs and aggressive tumor
phenotypes in women with a new diagnosis of breast cancer in the upstate of SC.
The study originally defined aggressive phenotype to be considered as anyone with
TNBC or high-grade tumors. The results from the analysis showed no significant results
with either Pearson's chi-square, χ 2(1) = 2.33, p = 0.1 or regression analysis, F(1/ 64) =
1.119, p = .29. However, when the study analyzed only high-grade tumors (df=1 and
95.0% confidence interval) it found significant results, F(1/ 64) = 4.40, p=. 036,
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association of high-grade tumors to GA (Tables 5.5a and 5.5b) was considered. This
shows that a GA predicts a high-grade tumor status.
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Table 5.5a
Crosstabulation of GAs and High-Grade Tumor*
Breast Cancer Susceptibility
GAs (Mutations and/or VUS)
No
Yes
High-Grade tumors
No
39 (81.3%)
9 (18.8%)
Yes
12 (57.1%)
9 (42.9%)
2
Note. χ = 4.40, df = 1. Numbers in parentheses indicate column percentages.
(p=.036)

Table 5.5b
Regression Analysis of GA and High-Grade Tumor*
Model
Sum of
df
F
Sig.
Squares
Regression
1
4.567
.036
Note. p= .036, df = 1, 95.0% Confidence Interval. Dependent Variable:
High-grade tumor and predictor: Genetic Alterations (GA).
*p<.05
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Research Hypothesis 2
Research hypothesis 2 sought to determine if the aggressive breast cancer tumor
phenotype is associated with a specific gene variant. Since there were no associations
between aggressive phenotype and specific GA in this study and the null hypothesis is
retained, it is concluded there is no specific GA associated with an aggressive breast
cancer tumor phenotype among 65 women.
Additional Analyses
High-grade breast tumors have be associated with inherited BRCA1 and BRCA2
mutations (Agnarsson, Jonasson, Björnsdottir, Barkardottir, Egilsson, & Sigurdsson,
1998). To further explore the study variables, the association of tumor markers with highgrade tumors in women with a new diagnosis of breast cancer was noted in this study. To
analyze data for this question, a Fisher’s Exact test was used and the results are shown in
Tables 5.6 through 5.8.
Additional data analysis based on ER percentage status showed significant results,
χ2(1) = 19.5, p <. 05, which indicated that the tumors with ER “negative” status or “low”
ER percentage tumors were associated with high-grade tumors when compared to “high”
ER percentage tumors (ER<1%: Negative, ER= 1-32%: Low, ER= 33% or higher: High).
Table 5.6 shows a summary of significant association between ER status and high-grade
tumors in this participant population, χ2(1) = 19.5, p = .001. The results from the crosstab
analysis are displayed in Table 5.7; the results showed that the tumors with PR “positive”
status are associated with not having high-grade tumors, χ2(1) = 11.07 p = .004. There is
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no significant difference between high-grade tumor and HER2 status as presented in
Table 5.8.
The data were also analyzed assessing the association between aggressive tumor
phenotype and GAs using Crosstabulation with bootstrapping option which showed nonsignificant results in accordance with what the analyses showed previously, χ2(1) = 2.32,
p =. 11.
This research was also designed to analyze the associations of the demographic
variables by aggressive tumor phenotype in women with a new diagnosis of breast
cancer, as well as the family history by aggressive phenotype. Table 5.9 shows a
summary of each demographic variable by aggressive tumor phenotype. Results of the
crosstab tests show that Race/Ethnicity was significantly different between aggressive
phenotypes (no vs. yes), χ2(1) = 6.15, p=. 013.
Research studies have shown that patients with germ-line mutations tend to have
more aggressive cancer phenotypes (Castro et al., 2013; Maier et al., 2014; Pern et al.,
2012). Since TNBC, high-grade tumor and disease stage are typically associated in the
clinical setting with aggressive breast cancer, these variables were analyzed to determine
if there was a significant difference among TNBC, high-grade tumor, or disease stage.
Chi-square analysis found no significant differences in any of these variables related to
their GAs except for high-grade tumors, χ2(1) = 4.40, p =. 038 and linear regression
analysis result, F (1/ 64) = 4.40, p =. 036.
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Table 5.6
Crosstabulation of ER Status and Presence of High-Grade Tumor
ER % Status
Negative*
Low*
High-Grade Tumor
No
4 (33.3%)
11 (50%)
Yes
8 (66.7%)
11 (50%)
2
Note. χ = 19.5, df = 1. Numbers in parentheses indicate column percentages.
ER<1%: Negative, ER= 1-32%: Low, ER= 33% or higher: High
*p < .05

High
55 (88.7%)
7 (11.3%)

Table 5.7
Crosstabulation of PR Status and Presence of High-Grade Tumor
PR Status*
Negative
Positive
High-Grade Tumor
No
18 (52.9%)
52 (83.9%)
Yes
16 (47.1%)
10 (16.1%)
2
Note. χ = 11.07, df = 1. Numbers in parentheses indicate column percentages.
*p < .05

Table 5.8
Crosstabulation of HER2 Status and Presence of High-Grade Tumor
HER2 Status
Negative
Positive
High-Grade Tumor
No
46 (74.2%)
18 (78.3%)
Yes
16 (25.8%)
5 (21.7%)
2
Note. χ = 1.68, df = 1. Numbers in parentheses indicate column percentages.
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Not Done
7 (58.3%)
5 (41.7%)

Table 5.9
Crosstabulation of Demographic Variables and Presence of Aggressive Phenotype
Aggressive Phenotype
χ2
No
Yes
2.92
Age
30 – 39
7 (10.6%)
7 (22.6%)
40 – 49
18 (27.3%)
6 (19.4%)
50 – 59
22 (33.3%)
10 (32.3%)
60 – 69
10 (15.1%)
5 (16.1%)
70 and Older
9 (13.6%)
3 (9.7%)
Race/Ethnicity
White
Non-White
Insurance Type
Private
Medicare
Medicaid
Education
9 – 12 Years
13 – 14 Years
15 or More
BMI
≤ 24.9(Normal Weight)
25.0 – 29.9(Overweight)
≥ 30.0(Obese)
*p < .05

6.15**
57 (74%)
9 (45%)

20 (26%)
11 (55%)
3.48

41 (62.1%)
16 (22.9%)
9 (13.3%)

24 (77.4%)
6 (19.4%)
1 (3.2%)
0.71

17 (25.7%)
27 (41%)
22 (33.3%)

10 (32.3%)
13 (41.9%)
8 (25.8%)
0.19

20 (30.3%)
23 (34.8%)
23 (34.8%)
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8 (25.8%)
11 (35.5%)
12 (38.7%)

Limitations
Although this research was meticulously prepared, there are some limitations to
the study which include:
•

only 101 participants were accrued due to time limitations. Since this was a nonprobability sample, the results may not be generalized;

•

because of the absence of genetic testing lab results for all participant samples,
the complete data on GAs were not available for analysis;

•

commercial panel results were not complete due to personal preference to not
join the study, insurance authorization requirements and/or the financial status of
participants. The study included all eligible women regardless of their insurance
status;

•

due to the study’s small sample size, a single variable made as “GA” which
defined as either having a genetic mutation or VUS. These variables were not
analyzed separately;

•

specific population of participants seeking treatments for breast cancer at the
cancer center;

•

potential confounding factors not accounted for due to the small sample size.
These confounding factors could include age distributions, ethnicity, inconsistent
information in the family history, requirement of hospital use by insurance
companies, insurance requirements for genetic testing and use of different
laboratories for the genetic testing.
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Conclusions
This research study has the potential to provide several contributions to patient
care. Because of the low sample size some results are difficult to discuss in light of the
population from which the sample was drawn but there are hints at potential application
to patient care.
Overall this study aimed to determine the associations between aggressive breast
cancer phenotype and breast cancer susceptibility gene mutations and their variants.
There was a significant difference between high-grade tumors and GAs, F (1/ 64) = 4.40,
p=. 036, among study participants emphasizing that GAs are associated with high-grade
tumors as it was reported by this research and other similar research studies (Castro et al.,
2013; Maier et al., 2014; Pern et al., 2012).
Additionally, this study revealed ER “negative” status or “low” ER percentage
tumors were associated with high-grade tumors when compared to “high” ER percentage
tumors (ER<1%: Negative, ER= 1-32%: Low, ER= 33% or higher: High), χ2(1) = 19.5, p
<. 05. It was also noted the population of non-white women have a significantly more
aggressive tumor phenotype when compared to other ethnicities χ2(1) = 6.15, p =. 013.
However, the results showed no significant differences between aggressive tumor
phenotypes (high-grade tumors and/or TNBC) and breast cancer GAs (commercial or
GGC mutation and/or VUS) in women at high risk for hereditary breast cancer
syndromes, χ2(1) = 2.33, p = 0.1. This could be due to the limitations of this study such as
small sample size, missing genetic testing results from the laboratories and the population
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of participants seeking treatments for breast cancer at the cancer center.
The study results also hint at the future potential for multi-panel genetic testing
not only for the women at high risk for germline mutations, but also for women with
high-grade breast tumor histology. Due to the study results an emphasis for considering
family history of cancer during decision-making regarding genetic testing continues to be
necessary for women at high risk for germline variants as well as their tumor biomarkers.
Some of the participants with GAs in this research had family history of other cancers
(not just breast and ovarian cancer) such as pancreatic cancer (participants #66 and # 96)
and colorectal cancer (participants #31, #61, #22, #28 and # 39). These results, although
small (43.6% of mutations and 66.7% of VUSs were from panel testing), indicate that
including multi-panel genetic testing that includes related cancer predisposition genes,
not just BRCA1 and BRCA2 genes, is essential to achieve better patient outcomes.
Currently, only women meeting the strict requirements for being at high risk for
hereditary breast and ovarian cancer are eligible for breast cancer genetic testing (NCCN,
2015a). Expansion of the scope of genetic testing eligibility based on tumor histology as
well as ER/PR/ HER2 biomarkers status brings the future of personalized treatment to
better patient outcome.
Future Research
While this dissertation reveals interesting phenomena associated with hereditary
breast cancer and the approach introduced providing a natural guide to future research,
there are still many unanswered questions to investigate. To enhance understanding of the
aggressive breast cancer associated with GAs and to determine future clinical application,
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the recommended future studies are summarized as follows:
•

evaluating the recognized association between the grade of tumors and
germ-line variants further to be confirmed with larger number of
participants first;

•

determining if there are more GAs in a larger population of women with
breast cancer that could predict the growth and progression of future
breast cancers in a woman;

•

developing another study to follow up on the incidental findings such as
participants with pancreatic cancer, participants #66 (with double VUS)
and # 96;

•

investigating if socioeconomic factors affecting genetic testing and how to
improve the quality of care for uninsured or underinsured patients;

•

comparing other important variables such as mammography reports, social
behavior (smoking and drinking habit) and lifestyle would be beneficial;

•

investigating the association between high-grade tumors and GAs in more
diverse population;

•

revising eligibility criteria for the future study to include patients from
diverse population as well as considering tumor biomarkers (ER, PR and
HER2 status) and tumor grade to eligibility criteria;

•

developing a mixed methods research study applying PMT is highly
recommended to be able to motivate the population of women to follow
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the prevention strategies to reduce their risk of another primary cancer
diagnosis specifically in women with diverse ethnic background. As noted
by this study previously, non-white women had a more aggressive
phenotype when compared to white women and this could be due to
several factors including lack of education about prevention and early
detection strategies. In order to educate and motivate the population of
women, applying four concepts of PMT is suggested for future studies
(severity of the health problem, vulnerability or risk of the threat, selfefficacy and response to the protective measures) (Helmes, 2002).
Summary
Breast cancer genetic testing guidelines established by NCCN suggest testing only
for the patients at high risk for hereditary breast and ovarian cancer based on very
specific guidelines (NCCN, 2015a). Although there are several research studies on cancer
and its epidemiology that have led to guidelines for early detection and risk reduction, a
low percentage of people (less than 0.2% of women in United States use Tamoxifen and
approximately 3% of Australian women follow the prevention guidelines) follow the
suggested strategies; especially those from diverse ethnicities (Ralph et al., 2014).
In summary, the study did predict associations between breast cancer
susceptibility GAs and high-grade tumors in women with a new diagnosis of breast
cancer and at high risk for hereditary breast cancer syndromes, χ2(1) = 4.40, p =. 038.
Having a high-grade breast tumor could be important in breast cancer genetic testing
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guidelines since results from this research study suggest that ER and PR markers as well
as ethnicity are predictive of aggressive tumor phenotype in the population of women
with breast cancer.
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CHAPTER SIX
SYNTHESIS
The American Cancer Society anticipates more than 200,000 new cases of
invasive breast cancer in 2015 (American Cancer Society, 2015) with 10% of the cases
believed to be the result of germline mutations (Tung et al., 2015). Family history of
breast cancer, ovarian cancer, pancreatic cancer and prostate cancer are all classified as
frequently identified in families with hereditary breast cancer syndromes (NCCN, 2015).
Moreover, breast cancer is influenced by ethnicity and race where African American
women in the United States tend to be diagnosed with a more aggressive type of breast
cancer as compared to Caucasian women (Boone, et al., 2014; Iqbal, et al., 2015).
Healthcare professionals have a critical role in care for patients in regards to
screening, diagnosis, treatment and translation of current genomic knowledge into
practice to disseminate better outcomes. Through extensive biomedical research,
advances in DNA sequencing have helped clinicians make progress in cancer screening,
prevention and treatment (Chin, Hahn, Getz, & Meyerson, 2011; Grada, & Weinbrecht,
2013; Hawthorn, Luce, Stei, & Rothschild, 2010; Staren, et al., 2014).
All chapters of this body of work present various aspects about aggressive breast
cancer; ATM and PALB2, two new high risk gene mutations that may cause malignant
disease much like the BRCA genes, aggressive inflammatory breast cancer (IBC),
application of a health promotion theory targeting women who need a plan to prevent or
detect another cancer at an early stage and multi-gene panel research to identify a high
susceptibility GA for breast cancer. The purpose of the dissertation work was to
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determine if breast cancer susceptibility genetic alterations (GA) could predict an
aggressive phenotype.
In order to better understand the new GAs associated with hereditary breast
cancer, the first manuscript (Chapter two) took an analytical look at breast cancer through
genomic investigation of two newly recognized genes; the ATM and PALB2 genes. A
comprehensive review and synthesis of current literature was completed to discuss
updates on guidelines for genetic testing and prevention strategies. According to the
newest version of the National Comprehensive Cancer Network (NCCN) guidelines
(Genetic/Familial High Risk Assessment: Breast and Ovarian, version 2.2015), patients
must meet one or more breast cancer risk assessment criteria in order to be eligible for
genetic testing for the hereditary breast and ovarian cancer (HBOC) syndrome (See
Figure 5.1) (NCCN, 2015). This review of literature concluded that multi-gene panels
testing to detect ATM and PALB2 gene mutations would be appropriate for the population
of individuals considered to be “high risk” for hereditary breast cancer syndromes, even
though the prevalence appears to be low; meaning there are other genes besides the well
known BRCA1 and BRCA2.
After careful consideration of multi-gene panel genetic testing, the second
manuscript took an in depth look at IBC (an aggressive type of breast cancer), the
mechanism of inflammation and potential causes of the aggressive IBC. The purpose of
the literature synthesis was to discuss IBC and explain disease pathogenesis, new
genomic discoveries, diagnosis and treatment. In the United States, 2.5 percent of new
breast cancer diagnoses are the rare and aggressive type of IBC with specific features
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such as edema, swelling, erythema, triple negative tumor markers, rapid metastasis and
poor prognosis (Fernandez, et al., 2013; Makower & Sparano, 2013; Robertson, et al.,
2010; Shkurnikov, et al, 2013). The results from this comprehensive synthesis of
literature based on the GA of IBC indicate that IBC has a heterogeneous and complex
nature. Further investigation and new personalized drug developments are critical to
achieve better prognosis and overall survival rate. Increased collaborative
interdisciplinary research is recommended to improve IBC awareness as well as
educating the general public about the disease that could improve patient outcomes.
Because women with germline mutations and breast cancer have a higher risk of
being diagnosed with another primary breast cancer as well as ovarian cancer, pancreatic
cancer, or melanoma, prevention from further cancer diagnosis is very critical for these
women. Considering the aggressive nature of breast cancer and the fact that the
percentage of individuals who follow the prevention guidelines are low (10 percent based
on chemoprevention studies) (Evans, Lalloo, Shenton, Boggis, & Howell, 2001; NCCN,
2015; Ralph et al., 2014), it is important to educate patients in prevention and early
detection strategies.
The dichotomy between the necessity and actual usage of screening and
prevention methods in high risk patients has led to incorporation of the Protection
Motivation Theory (PMT) into the third manuscript of this dissertation. This theory
could be used as a tool to offer education for women with breast cancer and have positive
breast cancer susceptibility GA. PMT is comprised of four concepts that effect decision
making: 1) severity of the health problem; 2) vulnerability or risk of the threat 3) self-
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efficacy; and, 4) response to protective measures that promote a health behavior (See
Figure 4.1) (Helmes, 2002; Maddux & Rogers, 1983; Ralph et al., 2014; Rogers, 1975).
Several studies have applied PMT to a health behavior using the same concepts including
research on breast cancer genetic testing, life style change and obesity, physical activity
adherence and skin cancer screening (Baghianimoghadam, Mohammadi, Noorbala, &
Mahmoodabad, 2011; Cyrus-David, & Strom, 2001; Frosch, Mello, & Lerman, 2005;
Grindley, Zizzi, & Nasypany, 2008; Helms, 2002; Lee et al., 2007; Morrison et al., 2010;
Ralph et al., 2014). The suggested pilot study would utilize the instruments applied to
these studies to assess the application of PMT to motivate patients with GAs to follow
screening and prevention strategies. This is a new approach with the theory for patients
with a diagnosis of aggressive breast cancer and a GA.
According to several research studies, there is a link between aggressive tumor
phenotype and GAs in different hereditary cancer syndromes (Castro et al., 2013; Maier
et al., 2014; Pern et al., 2012). Studies have shown triple negative breast cancer, an
aggressive phenotype, is seen in patients with mutations in BRCA1, BRCA2, PALB2 and
BRD7 genes (Pern et al., 2012).
Considering the importance of understanding the genetic mechanisms of breast
cancer and associations to phenotypic outcomes, the fifth chapter, a quantitative research
study, was developed. The purpose of this study was to determine (1) if breast cancer
susceptibility GAs are associated with an aggressive tumor phenotype in women with a
new diagnosis of breast cancer and (2) if the aggressive breast cancer tumor phenotype is
associated with a specific gene variant (s).
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The results predicted the association between breast cancer GA and high-grade
tumor phenotype in women with breast cancer, F (1/ 64) = 4.40, p=. 036 (See Table 5.5a
and 5.5b). The aggressive phenotype in this research is defined as either having triple
negative marker status or a high-grade tumor and GA is described as having a designated
mutation or variant of unknown significance (VUS) result from either Greenwood
Genetic Center (GGC) or commercial genetic testing laboratories. The results also
revealed that estrogen receptor (ER) or progesterone receptor (PR) status is associated
with breast cancer tumor grade status in a separate analysis (See Tables 5.6 through 5.8).
Despite an increasing knowledge in breast cancer genomics and studies evaluating
the disease based on different ethnic backgrounds, the guidelines for breast cancer
genetic testing eligibility are not focused on ethnicity (NCCN, 2015). This study revealed
that aggressive tumor phenotype is associated with non-white population of women
participated in the study, χ2(1) = 6.15, p=. 013. This suggests the need for
recommendations for genetic testing guidelines to be revised to include multi-panel
genetic testing for all eligible individuals as well as inclusion of tumor biomarkers and
ethnicity in eligibility criteria.
Summary
This dissertation reviewed and analyzed different aspects of aggressive breast
cancer such as ATM and PALB2 gene mutations, aggressive IBC, application of PMT and
multi-gene panel testing for breast cancer. Even though a small percentage of breast
cancer cases are the result of GAs (Tung et al., 2015), there are several guidelines and
protocols available to encourage the use of screening tools for early detection and
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prevention of developing breast cancer in women at high risk. However, current use of
the diagnostics and the chemoprevention agents is low (e.g., almost ten percent in
chemoprevention studies) (Evans et al., 2001; NCCN, 2015; Vogel, 2010).
This research analyzed ER, PR status and breast cancer tumor grades. Currently
genetic testing eligibility criteria are based on age, ethnicity, family history and negative
ER/PR/human epidermal growth factor 2 (HER2) status. This study suggests multi-panel
genetic testing based on tumor histology according to significant association between
having breast cancer GAs and an aggressive high-grade tumor phenotype, χ2(1) = 4.40,
p=. 038 might also be important.
After reviewing breast cancer genomics, aggressive IBC, PMT application in
breast cancer studies and multi- panel genetic testing, there are hints for the need to
change guidelines that could affect women at high risk to develop an aggressive breast
cancer. A synthesis of the work suggests the need for genetic testing for all women at
high risk for breast cancer. This should be in a timely manner to better guide treatment
and to implement strategies toward more personalized medicine. Applying PMT would
also be beneficial to educate patients, particularly in low income and minority ethnic
groups, to change their intention toward a healthy behavior.
Future research should: 1) include more participants in a replicative study with
complete genetic results to determine if there are more GAs in a larger population; 2)
develop another study to follow incidental findings; 3) investigate if socioeconomic
factors affecting genetic testing; 4) compare other essential variables; 5) revise eligibility
criteria for breast cancer genetic testing; 6) apply PMT to educate patients; and, 7)
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investigate more individuals from diverse populations.
With advances in genomic technology, the body of work of this dissertation
represents the urgent need to support similar studies. More studies would provide more
evidence to pave the path toward personalized medicine, particularly in breast cancer
research.
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Appendix D
Data Collection Sheet

Participant #:

Demographics

AGE
20-29 (0)
30-39 (1)
40-49 (2)
50-59 (3)
60-69 (4)
70-79 (5)
80-89 (6)
SEX
M (0)
F (1)
RACE
White (0)
Black (1)
Hispanic (2)
Other (3)
INSURANCE
Private (0)
Medicare (1)
Medicaid (2)
Uninsured (3)
COLLECTION
DATE
SPECIMEN
EDUCATION
9-12 years (0)
13-14 years (1)
15 or more (2)
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HEIGHT

WEIGHT

BMI
≤24.9 (0)
25-29.9 (1)
≥30

BREAST CANCER
MENOPAUSE
Pre menopausal (0)
Post menopausal (1)

CANCER SITE
Right breast (0)
Left breast (1)
Bilateral (2)
SENTINEL NODE
Sentinel Node Negative (0)
Sentinel Node Positive (1)

TUMOR SIZE
Size of malignancy 0-0.9 cm (0)
Size of malignancy > 1 cm (1)
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ER MARKER
ER - marker (0)
ER + marker (1)
Not done (2)
PR MARKER
PR – marker (0)
PR + marker (1)
Not done (2)
HER2 MARKER
HER2 – marker (0)
HER2 + marker (1)
Not done (2)
SURGICAL INTERVENTION
No surgery (0)
Lumpectomy (1)
Mastectomy (2)
Neoadjuvant + Unknown (3)
Neoadjuvant + Lumpectomy (4)
Neoadjuvant + Mastectomy (5)
Neoadjuvant only (6)
STAGE
Stage 0 (0)
Stage I (1)
Stage II A (2)
Stage II B (3)
Stage III A (4)
Stage III B (5)
Stage IV (6)
FAMILY HISTORY of BC
No (0)
Yes (1)
Siblings with Breast Cancer
No (0)
Yes (1)
Breast Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
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Breast Cancer Maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Ovarian Cancer
No (0)
Yes (1)
Ovarian Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Ovarian Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Prostate Cancer
No (0)
Yes (1)
Prostate Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Prostate Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Pancreatic Cancer
No (0)
Yes (1)
Pancreatic Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Pancreatic Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
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Blended generation (3)

Family HX of Male Breast Cancer
No (0)
Yes (1)
Male Breast Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Male Breast Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Gastric Cancer
No (0)
Yes (1)
Gastric Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Gastric Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Colorectal Cancer
No (0)
Yes (1)
Colorectal Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Colorectal Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
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Family HX of Thyroid Cancer
No (0)
Yes (1)
Thyroid Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Thyroid Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Uterine Cancer
No (0)
Yes (1)
Uterine Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Uterine Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Kidney Cancer
No (0)
Yes (1)
Kidney Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Kidney Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Sarcoma Cancer
No (0)
Yes (1)
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Sarcoma Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Sarcoma Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Brain Cancer
No (0)
Yes (1)
Brain Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Brain Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Leukemia
No (0)
Yes (1)
Leukemia Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Leukemia maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Gastrointestinal Cancer
No (0)
Yes (1)
Gastrointestinal Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
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Blended generation (3)

Gastrointestinal Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Family HX of Optic Glioma Cancer
No (0)
Yes (1)
Optic Glioma Cancer Paternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Optic Glioma Cancer maternal
1st generation (0)
2nd generation (1)
3rd generation (2)
Blended generation (3)
Sum of Family HX of all cancer types

Oncotype DX
Not done (0)
Low risk (1)
Intermediate risk (2)
High risk (3)
Other Signature Studies
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GGC Test Result
Negative (0)
Positive (1)
VUS (2)
Positive and VUS (3)
GGC MUTATION TYPE

GGC VUS TYPE
Commercial Genetic Testing
None (0)
Myriad BRCAnalysis (1)
Myriad Panel (2)
GeneDX (3)
Ambry: BRCAplus (4)
Ambry: GYNplus (5)
Ambry: BreastNext (6)
Ambry: Ovanext (7)
Ambry: Pancnext (8)
Ambry: Cancernext (9)
Ambry: Cancernext expanded (10)
Ambry: BRCA deletion/duplication analysis
(11)
Ambry: gene sequence and
deletion/duplication analysis (12)
Integrated Genetics: Comprehensive BRCA
1/2 Analysis (13)
Ambry: Colonext (14)
BreastAssure LabCorp (15)
Unknown (16)
Commercial Genetic Testing Result
Negative (0)
Positive (1)
VUS (2)
Positive & VUS (3)
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Commercial Genetic Testing Variant
Identified

VUS identified

Left Breast Tumor 1 grade
None (0)
Low (1)
Intermediate (2)
High (3)
Left Breast Tumor 2 grade
None (0)
Low (1)
Intermediate (2)
High (3)
Right Breast Tumor 1 grade
None (0)
Low (1)
Intermediate (2)
High (3)
Right Breast Tumor 2 grade
None (0)
Low (1)
Intermediate (2)
High (3)
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Second Primary
No (0)
Yes (1)

Second Primary Type

Primary 2 ER
ER – (0)
ER + (1)

Primary 2 PR
PR – (0)
PR + (1)

Primary 2 HER2
HER2 – (0)
HER2 + (1)
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